mappedGenes,riskAllele,traitName,pValue,orValue,ChemicalName,Interaction,InteractionActions
ABCA1,rs1800978-G,Alzheimer's disease,2e-9,1.06,Mercury,Mercury affects the expression of ABCA1 mRNA,affects^expression
ABCA1,rs1800978-G,Alzheimer's disease,2e-9,1.06,Methylmercury Compounds,Methylmercury Compounds affects the expression of ABCA1 mRNA,affects^expression
ABCA1,rs1800978-G,Alzheimer's disease,2e-9,1.06,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCA1 mRNA",affects^cotreatment|increases^expression
ABCA1,rs1800978-G,Alzheimer's disease,2e-9,1.06,methylmercuric chloride,methylmercuric chloride results in decreased expression of ABCA1 mRNA,decreases^expression
ABI3,rs616338-T,Alzheimer's disease,3e-14,1.32,methylmercury II,methylmercury II results in decreased expression of ABI3 mRNA,decreases^expression
ABLIM2,rs11947858-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",3e-6,1.2727755,Lead,Lead affects the expression of ABLIM2 mRNA,affects^expression
ADAM10,rs593742-?,Alzheimer's disease or family history of Alzheimer's disease,6e-11,1.06,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADAM10 mRNA,decreases^expression
ADAMTS1,rs2830489-T,Alzheimer's disease,2e-10,0.95,Lead,Lead affects the expression of ADAMTS1 mRNA,affects^expression
ADAMTS1,rs2830489-T,Alzheimer's disease,2e-10,0.95,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS1 mRNA",affects^cotreatment|increases^expression
ADAMTS1,rs2830489-T,Alzheimer's disease,2e-10,0.95,mercuric bromide,mercuric bromide results in increased expression of ADAMTS1 mRNA,increases^expression
ADAMTS1,rs2830489-T,Alzheimer's disease,2e-10,0.95,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADAMTS1 mRNA,decreases^expression
ADAMTS17,rs77466153-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,1.2951157,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADAMTS17 mRNA,decreases^expression
ADAMTS19,rs67540991-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-7,1.2765996,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADAMTS19 mRNA,decreases^expression
ADAMTS2,rs149568838-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.52560776,Lead,Lead affects the expression of ADAMTS2 mRNA,affects^expression
ADAMTS2,rs149568838-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.52560776,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA",affects^cotreatment|decreases^expression
ADAMTS2,rs149568838-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.52560776,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS2 mRNA",affects^cotreatment|decreases^expression
ADAMTS2,rs149568838-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.52560776,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADAMTS2 mRNA,decreases^expression
ADAMTS20,rs7295246-G,Alzheimer's disease (late onset),3e-7,1.07,mercuric bromide,mercuric bromide results in decreased expression of ADAMTS20 mRNA,decreases^expression
ADAMTS20,rs7295246-G,Alzheimer's disease (late onset),3e-7,1.07,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADAMTS20 mRNA,decreases^expression
ADCY10P1,rs116748189-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,0.5923841,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADCY10P1 mRNA",affects^cotreatment|decreases^expression
ADCY10P1,rs116748189-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,0.5923841,methylmercuric chloride,methylmercuric chloride results in decreased expression of ADCY10P1 mRNA,decreases^expression
AGAP1,rs12465126-A,Alzheimer's disease,2e-6,1.6,Lead,Lead affects the expression of AGAP1 mRNA,affects^expression
AGAP1,rs12465126-A,Alzheimer's disease,2e-6,1.6,methylmercuric chloride,methylmercuric chloride results in increased expression of AGAP1 mRNA,increases^expression
AGT,rs1977412-C,Alzheimer's disease with memory domain impairment,6e-7,1.5625,Lead,AGT protein binds to Lead,affects^binding
AHNAK,rs11828907-C,Alzheimer's disease (late onset),2e-7,4.4935546,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA",affects^cotreatment|increases^expression
AKAP6,rs2891226-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",6e-6,1.2104595,Lead,Lead affects the expression of AKAP6 mRNA,affects^expression
AKR1C3,rs140153888-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.2804352,Mercuric Chloride,Mercuric Chloride results in increased expression of AKR1C3 mRNA,increases^expression
AKR1C3,rs140153888-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.2804352,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C3 mRNA",affects^cotreatment|increases^expression
AKR1C3,rs140153888-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.2804352,lead acetate,lead acetate results in increased expression of AKR1C3 mRNA,increases^expression
AKR1C3,rs140153888-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.2804352,mercuric bromide,mercuric bromide results in increased expression of AKR1C3 mRNA,increases^expression
AKR1C3,rs140153888-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.2804352,methylmercuric chloride,methylmercuric chloride results in increased expression of AKR1C3 mRNA,increases^expression
ALCAM,rs2633682-?,Alzheimer's disease,9e-7,0.78,Lead,Lead affects the splicing of ALCAM mRNA,affects^splicing
ALCAM,rs2633682-?,Alzheimer's disease,9e-7,0.78,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA",affects^cotreatment|increases^expression
ALCAM,rs2633682-?,Alzheimer's disease,9e-7,0.78,mercuric bromide,mercuric bromide results in increased expression of ALCAM mRNA,increases^expression
ALCAM,rs2633682-?,Alzheimer's disease,9e-7,0.78,methylmercuric chloride,methylmercuric chloride results in decreased expression of ALCAM mRNA,decreases^expression
ANGPT2,rs2442629-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8692713,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA",affects^cotreatment|increases^expression
ANGPT2,rs2442629-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8692713,methylmercuric chloride,methylmercuric chloride results in increased expression of ANGPT2 mRNA,increases^expression
ANK1,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,Lead,Lead affects the expression of ANK1 mRNA,affects^expression
ANK1,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,Mercury,Mercury results in decreased expression of ANK1 mRNA,decreases^expression
ANK1,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK1 mRNA",affects^cotreatment|increases^expression
ANK1,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,mercuric bromide,mercuric bromide results in increased expression of ANK1 mRNA,increases^expression
ANK3,rs7068231-T,Alzheimer's disease,3e-13,0.95,Lead,Lead affects the splicing of ANK3 mRNA,affects^splicing
ANK3,rs7068231-T,Alzheimer's disease,3e-13,0.95,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANK3 mRNA",affects^cotreatment|increases^expression
ANK3,rs7068231-T,Alzheimer's disease,3e-13,0.95,methylmercuric chloride,methylmercuric chloride results in decreased expression of ANK3 mRNA,decreases^expression
ANO1,rs151107956-?,Alzheimer's disease in non-APOE e4 carriers,4e-6,2.976,Lead,Lead affects the methylation of ANO1 gene,affects^methylation
ANTXR1,rs7561207-?,Alzheimer's disease,4e-6,2.1267998,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANTXR1 mRNA",affects^cotreatment|increases^expression
ANTXR1,rs7561207-?,Alzheimer's disease,4e-6,2.1267998,mercuric bromide,mercuric bromide results in increased expression of ANTXR1 mRNA,increases^expression
ANTXR1,rs7561207-?,Alzheimer's disease,4e-6,2.1267998,methylmercuric chloride,methylmercuric chloride results in increased expression of ANTXR1 mRNA,increases^expression
ANXA10,rs185148823-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",8e-6,1.9380842,lead acetate,lead acetate results in increased expression of ANXA10 mRNA,increases^expression
ANXA2,rs28576649-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.2500706,Lead,ANXA2 protein binds to Lead,affects^binding
ANXA2,rs28576649-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.2500706,Mercury,Mercury results in increased expression of ANXA2 mRNA,increases^expression
ANXA2,rs28576649-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.2500706,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA",affects^cotreatment|increases^expression
ANXA2,rs28576649-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.2500706,mercuric bromide,mercuric bromide results in increased expression of ANXA2 mRNA,increases^expression
ANXA2,rs28576649-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.2500706,methylmercuric chloride,methylmercuric chloride results in increased expression of ANXA2 mRNA,increases^expression
AOPEP,rs186316953-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",3e-6,1.5782237,methylmercuric chloride,methylmercuric chloride results in decreased expression of AOPEP mRNA,decreases^expression
AP2A2,rs10751667-T,Alzheimer's disease (late onset),6e-7,1.0753,Mercury,Mercury results in decreased expression of AP2A2 mRNA,decreases^expression
APOC1,rs4420638-?,Alzheimer's disease,8e-149,3.45,methylmercuric chloride,methylmercuric chloride results in decreased expression of APOC1 mRNA,decreases^expression
APOC4,rs141441332-A,Alzheimer's disease (onset between ages 58 and 79),1e-11,2.57,methylmercuric chloride,methylmercuric chloride results in increased expression of APOC4 mRNA,increases^expression
APOE,rs429358-?,Alzheimer's disease,2e-303,3.21,Lead,Lead affects the expression of APOE protein,affects^expression
APOE,rs429358-?,Alzheimer's disease,2e-303,3.21,Mercury,APOE gene polymorphism affects the susceptibility to Mercury,affects^response to substance
APOE,rs429358-?,Alzheimer's disease,2e-303,3.21,methylmercuric chloride,methylmercuric chloride results in decreased expression of APOE mRNA,decreases^expression
APP,rs2154481-C,Alzheimer's disease,1e-12,0.95,Lead,[lead acetate results in increased abundance of Lead] promotes the reaction [APP protein binds to APP protein],affects^binding|increases^abundance|increases^reaction
APP,rs2154481-C,Alzheimer's disease,1e-12,0.95,Mercuric Chloride,Melatonin inhibits the reaction [Mercuric Chloride results in increased secretion of APP protein modified form],decreases^reaction|increases^secretion
APP,rs2154481-C,Alzheimer's disease,1e-12,0.95,Mercury,Estradiol inhibits the reaction [Mercury results in increased secretion of APP protein modified form],decreases^reaction|increases^secretion
APP,rs2154481-C,Alzheimer's disease,1e-12,0.95,lead acetate,[lead acetate co-treated with tolfenamic acid] results in decreased expression of APP mRNA,affects^cotreatment|decreases^expression
AREG,rs544215943-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6842157,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AREG mRNA",affects^cotreatment|increases^expression
AREG,rs544215943-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6842157,methylmercuric chloride,methylmercuric chloride results in increased expression of AREG mRNA,increases^expression
ARFGEF3,rs58375505-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 1),8e-6,0.5255,Mercuric Chloride,Mercuric Chloride results in decreased expression of ARFGEF3 mRNA,decreases^expression
ARFGEF3,rs58375505-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 1),8e-6,0.5255,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA",affects^cotreatment|decreases^expression
ARHGAP26,rs145833683-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-6,1.6233631,methylmercuric chloride,methylmercuric chloride results in increased expression of ARHGAP26 mRNA,increases^expression
ARHGAP45,rs112131072-A,Alzheimer's disease,2e-9,0.93,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP45 mRNA",affects^cotreatment|decreases^expression
ARHGAP45,rs112131072-A,Alzheimer's disease,2e-9,0.93,lead acetate,lead acetate results in increased expression of ARHGAP45 mRNA,increases^expression
ARHGEF28,rs74819680-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,1.3196942,Mercury,Mercury results in decreased expression of ARHGEF28 mRNA,decreases^expression
ARIH1,rs8038734-?,Posterior cortical atrophy and Alzheimer's disease,6e-6,2.1375377,methylmercuric chloride,methylmercuric chloride results in increased expression of ARIH1 mRNA,increases^expression
ARL6IP6,rs143517014-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.5506257,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARL6IP6 mRNA",affects^cotreatment|decreases^expression
ATM,rs56009889-?,Alzheimer's disease (late onset),6e-7,3.0578122,lead acetate,ATM protein affects the reaction [lead acetate results in decreased expression of COX4 protein],affects^reaction|decreases^expression
ATP11B,rs16833596-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-6,0.8458612,Mercuric Chloride,Mercuric Chloride results in decreased expression of ATP11B mRNA,decreases^expression
ATP11B,rs16833596-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-6,0.8458612,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP11B mRNA",affects^cotreatment|increases^expression
ATP5F1C,rs139967528-G,Alzheimer's disease (late onset),6e-10,6.119662,Lead,Lead affects the splicing of ATP5F1C mRNA,affects^splicing
ATP7B,rs7988558-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),9e-19,1.27,Lead,Lead affects the expression of ATP7B mRNA,affects^expression
ATP7B,rs7988558-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),9e-19,1.27,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP7B mRNA",affects^cotreatment|increases^expression
ATP7B,rs7988558-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),9e-19,1.27,methylmercuric chloride,methylmercuric chloride results in decreased expression of ATP7B mRNA,decreases^expression
AUTS2,rs17684339-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.80011487,Lead,Lead affects the splicing of AUTS2 mRNA,affects^splicing
AUTS2,rs17684339-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.80011487,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AUTS2 mRNA",affects^cotreatment|decreases^expression
AUTS2,rs17684339-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.80011487,methylmercuric chloride,methylmercuric chloride results in increased expression of AUTS2 mRNA,increases^expression
BANK1,rs149970512-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.5104384,Mercury,Mercury results in increased expression of BANK1 mRNA,increases^expression
BANK1,rs149970512-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.5104384,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BANK1 mRNA",affects^cotreatment|increases^expression
BCAM,rs28399637-A,Alzheimer's disease,3.9999999999999997e-25,1.535,Lead,Lead affects the expression of BCAM mRNA,affects^expression
BCL3,rs74607435-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),2e-19,0.74,Lead,Lead affects the expression of BCL3 mRNA,affects^expression
BICC1,rs556906573-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",5e-6,0.6015173,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BICC1 mRNA",affects^cotreatment|increases^expression
BLOC1S4,rs10222981-T,Alzheimer's disease with language domain impairment,1e-6,2.06,methylmercuric chloride,methylmercuric chloride results in decreased expression of BLOC1S4 mRNA,decreases^expression
BMAL1,rs143902215-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,1.8430098,Lead,Lead affects the expression of BMAL1 mRNA,affects^expression
BMP1,rs4348488-C,Alzheimer's disease with multiple cognitive domain impairments,3e-6,1.97,lead acetate,lead acetate results in decreased expression of BMP1 mRNA,decreases^expression
BMP6,rs11751537-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.2299826,mercuric bromide,mercuric bromide results in increased expression of BMP6 mRNA,increases^expression
C1GALT1,rs117803234-?,Alzheimer's disease,7e-8,3.765,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA",affects^cotreatment|increases^expression
C1GALT1,rs117803234-?,Alzheimer's disease,7e-8,3.765,methylmercuric chloride,methylmercuric chloride results in increased expression of C1GALT1 mRNA,increases^expression
CACNA1A,rs189753894-?,Late-onset Alzheimer’s disease in APOEe4 non-carriers,2e-8,1.787,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNA1A mRNA",affects^cotreatment|decreases^expression
CACNA1E,rs2804714-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 2),6e-6,1.439,Lead,Lead affects the expression of CACNA1E mRNA,affects^expression
CADM2,rs71316816-C,Alzheimer's disease in APOE e4+ carriers,9e-6,1.25,Lead,Lead affects the expression of CADM2 mRNA,affects^expression
CADM2,rs71316816-C,Alzheimer's disease in APOE e4+ carriers,9e-6,1.25,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CADM2 mRNA",affects^cotreatment|increases^expression
CADM2,rs71316816-C,Alzheimer's disease in APOE e4+ carriers,9e-6,1.25,mercuric bromide,mercuric bromide results in increased expression of CADM2 mRNA,increases^expression
CADM2,rs71316816-C,Alzheimer's disease in APOE e4+ carriers,9e-6,1.25,methylmercuric chloride,methylmercuric chloride results in decreased expression of CADM2 mRNA,decreases^expression
CADPS,rs1452075-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),6e-6,2.031,Lead,Lead affects the splicing of CADPS mRNA,affects^splicing
CADPS,rs1452075-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),6e-6,2.031,methylmercuric chloride,methylmercuric chloride results in decreased expression of CADPS mRNA,decreases^expression
CADPS2,rs146484756-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,0.61841226,methylmercuric chloride,methylmercuric chloride results in decreased expression of CADPS2 mRNA,decreases^expression
CAMSAP1,rs149524209-?,Alzheimer's disease (age of onset) in APOE e4 non-carriers,1e-6,4.44,Lead,Lead results in decreased expression of CAMSAP1 mRNA,decreases^expression
CAMSAP1,rs149524209-?,Alzheimer's disease (age of onset) in APOE e4 non-carriers,1e-6,4.44,methylmercuric chloride,methylmercuric chloride results in decreased expression of CAMSAP1 mRNA,decreases^expression
CARS1,rs116088813-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.69246334,Lead,Lead affects the methylation of CARS1 gene,affects^methylation
CARS1,rs116088813-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.69246334,mercuric bromide,mercuric bromide results in increased expression of CARS1 mRNA,increases^expression
CARS1,rs116088813-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.69246334,methylmercuric chloride,methylmercuric chloride results in increased expression of CARS1 mRNA,increases^expression
CBX2,rs142486042-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,1.5265343,Lead,Lead affects the expression of CBX2 mRNA,affects^expression
CBX4,rs115471594-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.66904765,lead acetate,lead acetate results in increased expression of CBX4 mRNA,increases^expression
CBX4,rs115471594-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.66904765,methylmercuric chloride,methylmercuric chloride results in increased expression of CBX4 mRNA,increases^expression
CCDC171,rs4961664-?,Alzheimer's disease,4e-6,1.2335871,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC171 mRNA",affects^cotreatment|decreases^expression
CCDC171,rs4961664-?,Alzheimer's disease,4e-6,1.2335871,methylmercuric chloride,methylmercuric chloride results in decreased expression of CCDC171 mRNA,decreases^expression
CCDC91,rs148377161-T,Alzheimer's disease,2e-8,3.312,methylmercuric chloride,methylmercuric chloride results in decreased expression of CCDC91 mRNA,decreases^expression
CCT3,rs55829084-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),8e-6,2.377,Lead,Lead affects the expression of CCT3 mRNA,affects^expression
CD2AP,rs7767350-T,Alzheimer's disease,8e-22,1.08,methylmercuric chloride,methylmercuric chloride results in decreased expression of CD2AP mRNA,decreases^expression
CDH12,rs200347682-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-7,1.3973813,Lead,Lead affects the methylation of CDH12 gene,affects^methylation
CDH13,rs111723950-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",9e-7,0.70539314,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH13 mRNA",affects^cotreatment|increases^expression
CDH13,rs111723950-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",9e-7,0.70539314,mercuric bromide,mercuric bromide results in increased expression of CDH13 mRNA,increases^expression
CDH13,rs111723950-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",9e-7,0.70539314,methylmercuric chloride,methylmercuric chloride results in increased expression of CDH13 mRNA,increases^expression
CDH18,rs1281128605-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,0.5595625,Lead,Lead affects the expression of CDH18 mRNA,affects^expression
CDH18,rs1281128605-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,0.5595625,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA",affects^cotreatment|increases^expression
CDH18,rs1281128605-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,0.5595625,methylmercuric chloride,methylmercuric chloride results in increased expression of CDH18 mRNA,increases^expression
CDH4,rs77835421-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,0.6554718,Lead,Lead affects the methylation of CDH4 gene,affects^methylation
CDH7,rs111940630-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.552004,mercuric bromide,mercuric bromide results in decreased expression of CDH7 mRNA,decreases^expression
CDH7,rs111940630-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.552004,methylmercuric chloride,methylmercuric chloride results in increased expression of CDH7 mRNA,increases^expression
CDIPTOSP,rs150987621-T,Alzheimer's disease,5e-8,1.8,methylmercuric chloride,methylmercuric chloride results in increased expression of CDIPTOSP mRNA,increases^expression
CDKL1,rs61981931-?,Alzheimer's disease (age of onset) (adjusted for APOE e4 carrier status),2e-6,0.824,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDKL1 mRNA",affects^cotreatment|decreases^expression
CDKN2B,rs3217980-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.8010756,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDKN2B mRNA",affects^cotreatment|increases^expression
CDKN2B,rs3217980-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.8010756,lead acetate,lead acetate results in increased expression of CDKN2B mRNA,increases^expression
CDKN3,rs374535490-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,1.501403,Mercury,Mercury results in increased expression of CDKN3 mRNA,increases^expression
CDR2L,rs71380849-A,Alzheimer's disease in APOE e4- carriers,9e-7,1.47,methylmercuric chloride,methylmercuric chloride results in increased expression of CDR2L mRNA,increases^expression
CELF1,rs10838725-C,Alzheimer's disease (late onset),1e-8,1.08,methylmercuric chloride,methylmercuric chloride results in increased expression of CELF1 mRNA,increases^expression
CELF2,rs62209-C,Alzheimer's disease (late onset),2e-7,2.04,Mercuric Chloride,Mercuric Chloride results in decreased expression of CELF2 mRNA,decreases^expression
CELF2,rs62209-C,Alzheimer's disease (late onset),2e-7,2.04,methylmercuric chloride,methylmercuric chloride results in decreased expression of CELF2 mRNA,decreases^expression
CELSR1,rs13054402-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs clinical) (case-control set 1),3e-6,0.2539,methylmercuric chloride,methylmercuric chloride results in decreased expression of CELSR1 mRNA,decreases^expression
CHD2,rs12594991-?,Alzheimer's disease in APOE e4+ carriers,2e-7,2.21,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CHD2 mRNA",affects^cotreatment|decreases^expression
CHD2,rs12594991-?,Alzheimer's disease in APOE e4+ carriers,2e-7,2.21,methylmercuric chloride,methylmercuric chloride results in decreased expression of CHD2 mRNA,decreases^expression
CHN2,rs12155094-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.7078663,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHN2 mRNA",affects^cotreatment|increases^expression
CHN2,rs12155094-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.7078663,methylmercuric chloride,methylmercuric chloride results in decreased expression of CHN2 mRNA,decreases^expression
CLDN18,rs16847609-A,Alzheimer's disease in APOE e4- carriers,5e-7,1.19,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA",affects^cotreatment|increases^expression
CLDN18,rs16847609-A,Alzheimer's disease in APOE e4- carriers,5e-7,1.19,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN18 mRNA",affects^cotreatment|increases^expression
CLU,rs11787077-T,Alzheimer's disease,2e-44,0.91,Lead,Lead affects the expression of CLU mRNA,affects^expression
CLU,rs11787077-T,Alzheimer's disease,2e-44,0.91,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA",affects^cotreatment|increases^expression
CLYBL,rs9517934-?,Alzheimer's disease in APOE e4+ carriers,4e-6,1.896,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLYBL mRNA",affects^cotreatment|decreases^expression
CLYBL,rs9517934-?,Alzheimer's disease in APOE e4+ carriers,4e-6,1.896,lead acetate,[sodium arsenite co-treated with lead acetate] results in increased expression of CLYBL protein,affects^cotreatment|increases^expression
CMTM5,rs74037001-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 2),3e-6,0.5796,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CMTM5 mRNA",affects^cotreatment|decreases^expression
CMTM5,rs74037001-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 2),3e-6,0.5796,methylmercuric chloride,methylmercuric chloride results in decreased expression of CMTM5 mRNA,decreases^expression
CNTN4,rs57442028-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,1.7358549,methylmercuric chloride,methylmercuric chloride results in decreased expression of CNTN4 mRNA,decreases^expression
CNTN6,rs72997522-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.6940125,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN6 mRNA",affects^cotreatment|increases^expression
CNTNAP2,rs117834366-A,Alzheimer’s disease and/or vascular dementia (clinical subgroup VaD++),2e-8,6.03,methylmercuric chloride,methylmercuric chloride results in increased expression of CNTNAP2 mRNA,increases^expression
COBL,rs113603769-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",8e-6,1.2840254,methylmercuric chloride,methylmercuric chloride results in increased expression of COBL mRNA,increases^expression
COL12A1,rs73462024-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,0.8609662,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL12A1 mRNA",affects^cotreatment|increases^expression
COL12A1,rs73462024-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,0.8609662,mercuric bromide,mercuric bromide results in increased expression of COL12A1 mRNA,increases^expression
COL12A1,rs73462024-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,0.8609662,methylmercuric chloride,methylmercuric chloride results in increased expression of COL12A1 mRNA,increases^expression
COL21A1,rs189031305-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-6,0.64268535,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL21A1 mRNA",affects^cotreatment|increases^expression
COL21A1,rs189031305-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-6,0.64268535,methylmercuric chloride,methylmercuric chloride results in decreased expression of COL21A1 mRNA,decreases^expression
COL25A1,rs10019747-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,1.3624711,Lead,Lead affects the expression of COL25A1 mRNA,affects^expression
COL6A3,rs10177231-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,6.513,Lead,Lead affects the methylation of COL6A3 gene,affects^methylation
COL6A3,rs10177231-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,6.513,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA",affects^cotreatment|increases^expression
COL6A3,rs10177231-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,6.513,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA",affects^cotreatment|increases^expression
CPNE8,rs12827647-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",1e-6,1.4769808,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE8 mRNA",affects^cotreatment|increases^expression
CPS1,rs178585-C,Alzheimer's disease in APOE e4+ carriers,4e-6,1.13,Mercury,[Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate co-treated with lead nitrate co-treated with Mercury] results in decreased expression of CPS1 mRNA,affects^cotreatment|decreases^expression
CPS1,rs178585-C,Alzheimer's disease in APOE e4+ carriers,4e-6,1.13,lead nitrate,[Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate co-treated with lead nitrate co-treated with Mercury] results in decreased expression of CPS1 mRNA,affects^cotreatment|decreases^expression
CPS1,rs178585-C,Alzheimer's disease in APOE e4+ carriers,4e-6,1.13,methylmercuric chloride,methylmercuric chloride results in decreased expression of CPS1 mRNA,decreases^expression
CST3,rs13041727-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.76781994,Lead,"[Metals, Heavy results in increased abundance of Lead] which results in increased secretion of CST3 protein",increases^abundance|increases^secretion
CST3,rs13041727-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.76781994,Mercury,"[Metals, Heavy results in increased abundance of Mercury] which results in increased secretion of CST3 protein",increases^abundance|increases^secretion
CST3,rs13041727-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.76781994,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST3 mRNA",affects^cotreatment|increases^expression
CST4,rs13041727-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.76781994,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST4 mRNA",affects^cotreatment|increases^expression
CST4,rs13041727-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.76781994,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST4 mRNA",affects^cotreatment|increases^expression
CST6,rs12785292-A,Alzheimer's disease,1e-9,2.44,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CST6 mRNA",affects^cotreatment|increases^expression
CTNND2,rs2907292-?,Alzheimer's disease in non-APOE e4 carriers,9e-7,7.512,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA",affects^cotreatment|decreases^expression
CTNND2,rs2907292-?,Alzheimer's disease in non-APOE e4 carriers,9e-7,7.512,mercuric bromide,mercuric bromide results in decreased expression of CTNND2 mRNA,decreases^expression
CTNND2,rs2907292-?,Alzheimer's disease in non-APOE e4 carriers,9e-7,7.512,methylmercuric chloride,methylmercuric chloride results in decreased expression of CTNND2 mRNA,decreases^expression
CTSB,rs1065712-C,Alzheimer's disease,2e-9,1.09,Ethylmercury Compounds,Ethylmercury Compounds results in increased expression of CTSB protein,increases^expression
CTSB,rs1065712-C,Alzheimer's disease,2e-9,1.09,Methylmercury Compounds,BAX protein affects the reaction [Methylmercury Compounds affects the localization of CTSB protein],affects^localization|affects^reaction
CTSB,rs1065712-C,Alzheimer's disease,2e-9,1.09,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTSB mRNA",affects^cotreatment|increases^expression
CTSH,rs12592898-A,Alzheimer's disease,4e-9,0.94,Lead,Lead affects the expression of CTSH mRNA,affects^expression
CUL3,rs60430611-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.67583925,Methylmercury Compounds,Methylmercury Compounds results in decreased expression of CUL3 mRNA,decreases^expression
CUL3,rs60430611-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.67583925,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA",affects^cotreatment|decreases^expression
CUL3,rs60430611-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.67583925,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA",affects^cotreatment|decreases^expression
CUL3,rs60430611-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.67583925,methylmercuric chloride,methylmercuric chloride results in decreased expression of CUL3 mRNA,decreases^expression
CUZD1,rs184924400-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-7,0.47678006,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CUZD1 mRNA",affects^cotreatment|increases^expression
CUZD1,rs184924400-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-7,0.47678006,methylmercuric chloride,methylmercuric chloride results in decreased expression of CUZD1 mRNA,decreases^expression
CYB561,rs4277405-C,Alzheimer's disease,9e-20,0.94,Mercury,Mercury results in decreased expression of CYB561 mRNA,decreases^expression
CYRIA,rs75225674-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-6,0.7829394,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA",affects^cotreatment|increases^expression
CYYR1,rs2830489-T,Alzheimer's disease,2e-10,0.95,methylmercuric chloride,methylmercuric chloride results in increased expression of CYYR1 mRNA,increases^expression
DAB1,rs112437613-T,Alzheimer's disease in APOE E4 homozygosity,5e-9,2.28,Mercury,Mercury results in increased expression of DAB1 mRNA,increases^expression
DAB1,rs112437613-T,Alzheimer's disease in APOE E4 homozygosity,5e-9,2.28,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA",affects^cotreatment|decreases^expression
DAB1,rs112437613-T,Alzheimer's disease in APOE E4 homozygosity,5e-9,2.28,mercuric bromide,mercuric bromide results in decreased expression of DAB1 mRNA,decreases^expression
DACH1,rs147462581-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-7,1.6832055,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DACH1 mRNA",affects^cotreatment|decreases^expression
DACH1,rs147462581-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-7,1.6832055,methylmercuric chloride,methylmercuric chloride results in decreased expression of DACH1 mRNA,decreases^expression
DACH2,rs5969117-C,Alzheimer's disease,1e-6,1.490488,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA",affects^cotreatment|increases^expression
DCC,rs147426078-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,7.995,Lead,Lead affects the expression of DCC mRNA,affects^expression
DCC,rs147426078-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,7.995,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA",affects^cotreatment|increases^expression
DCLK2,rs114766276-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-7,1.3631525,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA",affects^cotreatment|decreases^expression
DCLK2,rs114766276-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-7,1.3631525,mercuric bromide,mercuric bromide results in decreased expression of DCLK2 mRNA,decreases^expression
DCLK2,rs114766276-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-7,1.3631525,methylmercuric chloride,methylmercuric chloride results in decreased expression of DCLK2 mRNA,decreases^expression
DEPTOR,rs1464277-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 3),5e-6,0.692,Lead,Lead affects the expression of DEPTOR mRNA,affects^expression
DEPTOR,rs1464277-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 3),5e-6,0.692,methylmercuric chloride,methylmercuric chloride results in decreased expression of DEPTOR mRNA,decreases^expression
DIO2,rs7155666-A,Alzheimer's disease,8e-10,2.44,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIO2 mRNA",affects^cotreatment|increases^expression
DIRAS2,rs183428791-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),2e-16,1.28,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIRAS2 mRNA",affects^cotreatment|increases^expression
DLG2,rs72945810-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,1.5224183,Lead,Lead affects the expression of DLG2 mRNA,affects^expression
DMAC1,rs1416585-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",2e-6,0.7812969,methylmercuric chloride,methylmercuric chloride results in decreased expression of DMAC1 mRNA,decreases^expression
DMD,rs5972406-?,Alzheimer's disease (clinical cases)  (r-XCI inactivation),1e-6,1.143,Lead,Lead affects the expression of DMD mRNA,affects^expression
DNAH1,rs113887954-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",1e-5,2.4198365,Mercury,Mercury results in decreased expression of DNAH1 mRNA,decreases^expression
DNAL1,rs12587545-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,1.1951839,Lead,Lead results in decreased expression of DNAL1 mRNA,decreases^expression
DOK6,rs113422942-CA,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",3e-6,1.1783321,Lead,Lead affects the expression of DOK6 mRNA,affects^expression
DSEL,rs1210782962-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,1.3396387,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSEL mRNA",affects^cotreatment|increases^expression
DSEL,rs1210782962-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,1.3396387,methylmercuric chloride,methylmercuric chloride results in decreased expression of DSEL mRNA,decreases^expression
EBF1,rs75972093-?,Alzheimer's disease in non-APOE e4 carriers,1e-6,6.418,mercuric bromide,mercuric bromide results in decreased expression of EBF1 mRNA,decreases^expression
EBF1,rs75972093-?,Alzheimer's disease in non-APOE e4 carriers,1e-6,6.418,methylmercuric chloride,methylmercuric chloride results in increased expression of EBF1 mRNA,increases^expression
ECHDC3,rs7912495-G,Alzheimer's disease,1e-18,1.06,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECHDC3 mRNA",affects^cotreatment|decreases^expression
EFHD1,rs10193553-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",8e-7,0.7475157,methylmercuric chloride,methylmercuric chloride results in decreased expression of EFHD1 mRNA,decreases^expression
EGFR,rs76928645-T,Alzheimer's disease,2e-10,0.93,Mercuric Chloride,Mercuric Chloride results in increased expression of EGFR mRNA,increases^expression
EGFR,rs76928645-T,Alzheimer's disease,2e-10,0.93,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EGFR mRNA",affects^cotreatment|increases^expression
EGFR,rs76928645-T,Alzheimer's disease,2e-10,0.93,lead acetate,"4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]",decreases^reaction|increases^phosphorylation
EGFR,rs76928645-T,Alzheimer's disease,2e-10,0.93,lead nitrate,EGFR mutant form affects the reaction [lead nitrate results in increased expression of PLA2G4A mRNA],affects^reaction|increases^expression
EGFR,rs76928645-T,Alzheimer's disease,2e-10,0.93,methylmercuric chloride,methylmercuric chloride results in increased expression of EGFR mRNA,increases^expression
EGLN3,rs35833468-?,Alzheimer's disease (late onset),3e-6,1.0869565,methylmercuric chloride,methylmercuric chloride results in decreased expression of EGLN3 mRNA,decreases^expression
EIF4E2,rs10193553-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",8e-7,0.7475157,Lead,Lead results in decreased expression of EIF4E2 mRNA,decreases^expression
EIF4E3,rs830662-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,0.73808223,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA",affects^cotreatment|decreases^expression
EIF4E3,rs830662-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,0.73808223,mercuric bromide,mercuric bromide results in decreased expression of EIF4E3 mRNA,decreases^expression
EIF4E3,rs830662-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,0.73808223,methylmercuric chloride,methylmercuric chloride results in decreased expression of EIF4E3 mRNA,decreases^expression
EMSY,rs190466244-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.7062534,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMSY mRNA",affects^cotreatment|decreases^expression
EMSY,rs190466244-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.7062534,methylmercuric chloride,methylmercuric chloride results in decreased expression of EMSY mRNA,decreases^expression
EPHB1,rs200299300-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,0.5332846,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB1 mRNA",affects^cotreatment|decreases^expression
EPHB1,rs200299300-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,0.5332846,mercuric bromide,mercuric bromide results in decreased expression of EPHB1 mRNA,decreases^expression
EPHB1,rs200299300-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,0.5332846,methylmercuric chloride,methylmercuric chloride results in decreased expression of EPHB1 mRNA,decreases^expression
ERBB4,rs140239415-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.5959491,methylmercuric chloride,methylmercuric chloride results in decreased expression of ERBB4 mRNA,decreases^expression
ERO1B,rs79144457-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-7,1.4547005,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA",affects^cotreatment|decreases^expression
ERO1B,rs79144457-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-7,1.4547005,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA",affects^cotreatment|decreases^expression
ESRRB,rs2008064-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3),3e-6,2.394,Lead,Lead affects the methylation of ESRRB gene,affects^methylation
ETV5,rs9290830-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-6,0.8694452,methylmercuric chloride,methylmercuric chloride results in increased expression of ETV5 mRNA,increases^expression
EXPH5,rs34386774-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.13917,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EXPH5 mRNA",affects^cotreatment|increases^expression
FAM107A,rs143997208-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,0.6659105,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM107A mRNA",affects^cotreatment|decreases^expression
FAM107A,rs143997208-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,0.6659105,methylmercuric chloride,methylmercuric chloride results in decreased expression of FAM107A mRNA,decreases^expression
FAM210B,rs117000803-?,Alzheimer's disease in APOE e4+ carriers,4e-6,7.045,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM210B mRNA",affects^cotreatment|increases^expression
FAM83E,rs433852-?,Posterior cortical atrophy and Alzheimer's disease,8e-6,1.6849171,Lead,Lead affects the methylation of FAM83E gene,affects^methylation
FANCD2,rs1552244-A,Alzheimer's disease,2e-6,1.32,Lead,Lead affects the expression of FANCD2 mRNA,affects^expression
FAR2,rs148377161-T,Alzheimer's disease,2e-8,3.312,methylmercuric chloride,methylmercuric chloride results in decreased expression of FAR2 mRNA,decreases^expression
FBXL13,rs77104831-?,Alzheimer's disease,2e-6,4.27716,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL13 mRNA",affects^cotreatment|decreases^expression
FEM1B,rs78511923-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",3e-6,1.3710817,Lead,Lead affects the expression of FEM1B mRNA,affects^expression
FEM1B,rs78511923-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",3e-6,1.3710817,methylmercuric chloride,methylmercuric chloride results in decreased expression of FEM1B mRNA,decreases^expression
FERMT2,rs17125924-G,Alzheimer's disease,8e-16,1.1,methylmercuric chloride,methylmercuric chloride results in increased expression of FERMT2 mRNA,increases^expression
FGGY,rs1390695-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",5e-6,1.5110428,methylmercuric chloride,methylmercuric chloride results in decreased expression of FGGY mRNA,decreases^expression
FLNB,rs1658366-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),6e-6,0.3749,Mercury,Mercury results in increased expression of FLNB mRNA,increases^expression
FLNB,rs1658366-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),6e-6,0.3749,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLNB mRNA",affects^cotreatment|increases^expression
FLNB,rs1658366-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),6e-6,0.3749,mercuric bromide,mercuric bromide results in increased expression of FLNB mRNA,increases^expression
FLNB,rs1658366-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),6e-6,0.3749,methylmercuric chloride,methylmercuric chloride results in increased expression of FLNB mRNA,increases^expression
FLRT2,rs10142223-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,0.86901057,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLRT2 mRNA",affects^cotreatment|increases^expression
FLRT2,rs10142223-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,0.86901057,lead acetate,lead acetate results in increased expression of FLRT2 mRNA,increases^expression
FLRT2,rs10142223-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,0.86901057,methylmercuric chloride,methylmercuric chloride results in decreased expression of FLRT2 mRNA,decreases^expression
FNIP1,rs758324-T,Alzheimer's disease in APOE e4- carriers,4e-7,1.1627907,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FNIP1 mRNA",affects^cotreatment|increases^expression
FNIP1,rs758324-T,Alzheimer's disease in APOE e4- carriers,4e-7,1.1627907,methylmercuric chloride,methylmercuric chloride results in increased expression of FNIP1 mRNA,increases^expression
FOXP2,rs7782412-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,0.861483,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXP2 mRNA",affects^cotreatment|increases^expression
FRAS1,rs58815656-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,0.6621256,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FRAS1 mRNA",affects^cotreatment|increases^expression
FRAS1,rs58815656-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,0.6621256,methylmercuric chloride,methylmercuric chloride results in increased expression of FRAS1 mRNA,increases^expression
FRMD4B,rs116823421-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,0.60902256,Lead,Lead affects the methylation of FRMD4B gene,affects^methylation
FRMD4B,rs116823421-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,0.60902256,methylmercuric chloride,methylmercuric chloride results in decreased expression of FRMD4B mRNA,decreases^expression
FST,rs35868327-T,Alzheimer's disease (late onset),3e-7,1.4705882,methylmercuric chloride,methylmercuric chloride results in increased expression of FST mRNA,increases^expression
FSTL5,rs200867006-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-6,0.66351753,methylmercuric chloride,methylmercuric chloride results in increased expression of FSTL5 mRNA,increases^expression
FTH1P5,rs4533991-T,Alzheimer's disease with no specific cognitive domain impairment,2e-6,1.32,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FTH1P5 mRNA",affects^cotreatment|increases^expression
FTH1P5,rs4533991-T,Alzheimer's disease with no specific cognitive domain impairment,2e-6,1.32,methylmercuric chloride,methylmercuric chloride results in increased expression of FTH1P5 mRNA,increases^expression
GAB2,rs2373115-G,Alzheimer's disease (late onset),1e-10,4.06,methylmercuric chloride,methylmercuric chloride results in increased expression of GAB2 mRNA,increases^expression
GABRB3,rs116431532-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,0.55477095,Mercuric Chloride,"[NOG protein co-treated with Mercuric Chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA",affects^cotreatment|increases^expression
GABRB3,rs116431532-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,0.55477095,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA",affects^cotreatment|increases^expression
GABRB3,rs116431532-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,0.55477095,mercuric bromide,mercuric bromide results in increased expression of GABRB3 mRNA,increases^expression
GABRB3,rs116431532-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,0.55477095,methylmercuric chloride,methylmercuric chloride results in increased expression of GABRB3 mRNA,increases^expression
GABRG3,rs7402147-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,1.1115996,Lead,Lead affects the expression of GABRG3 mRNA,affects^expression
GALNT15,rs17041810-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.7408182,Lead,Lead affects the expression of GALNT15 mRNA,affects^expression
GALNT15,rs17041810-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.7408182,lead acetate,lead acetate results in decreased expression of GALNT15 mRNA,decreases^expression
GALNT17,rs10275428-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,1.4015797,Lead,Lead affects the expression of GALNT17 mRNA,affects^expression
GALR1,rs72987909-?,Alzheimer's disease in APOE e4+ carriers,1e-6,2.077,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALR1 mRNA",affects^cotreatment|increases^expression
GFPT1,rs77731149-?,Alzheimer's disease in APOE e4+ carriers,5e-6,3.733,Lead,Lead affects the expression of GFPT1 mRNA,affects^expression
GFPT1,rs77731149-?,Alzheimer's disease in APOE e4+ carriers,5e-6,3.733,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFPT1 mRNA",affects^cotreatment|increases^expression
GFPT1,rs77731149-?,Alzheimer's disease in APOE e4+ carriers,5e-6,3.733,methylmercuric chloride,methylmercuric chloride results in increased expression of GFPT1 mRNA,increases^expression
GGPS1,rs10925482-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,1.1870842,methylmercuric chloride,methylmercuric chloride results in decreased expression of GGPS1 mRNA,decreases^expression
GLI2,rs34875362-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.85941786,methylmercuric chloride,methylmercuric chloride results in increased expression of GLI2 mRNA,increases^expression
GLI3,rs78046089-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.563927,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLI3 mRNA",affects^cotreatment|decreases^expression
GLI3,rs78046089-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.563927,methylmercuric chloride,methylmercuric chloride results in decreased expression of GLI3 mRNA,decreases^expression
GLRX,rs116568941-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6284033,Mercuric Chloride,Mercuric Chloride affects the metabolism of GLRX protein,affects^metabolic processing
GLRX,rs116568941-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6284033,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX mRNA",affects^cotreatment|increases^expression
GLRX,rs116568941-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6284033,methylmercuric chloride,methylmercuric chloride results in increased expression of and results in decreased activity of GLRX protein,decreases^activity|increases^expression
GPATCH2L,rs2008064-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3),3e-6,2.394,methylmercuric chloride,methylmercuric chloride results in decreased expression of GPATCH2L mRNA,decreases^expression
GPBP1,rs10071932-?,Posterior cortical atrophy and Alzheimer's disease,9e-6,1.4506525,methylmercuric chloride,methylmercuric chloride results in decreased expression of GPBP1 mRNA,decreases^expression
GPC6,rs9516245-?,Alzheimer's disease,4e-7,1.73,Lead,Lead affects the expression of GPC6 mRNA,affects^expression
GRIK3,rs11263955-?,Alzheimer's disease in APOE e4+ carriers,5e-6,1.974,Phenylmercuric Acetate,Phenylmercuric Acetate results in decreased expression of GRIK3 mRNA,decreases^expression
GRIK3,rs11263955-?,Alzheimer's disease in APOE e4+ carriers,5e-6,1.974,methylmercuric chloride,methylmercuric chloride results in decreased expression of GRIK3 mRNA,decreases^expression
GTF2F1,rs192565310-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-7,0.70730025,Lead,Lead results in decreased expression of GTF2F1 mRNA,decreases^expression
GUCY1A2,rs11211840-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",1e-5,1.4219085,Lead,Lead affects the expression of GUCY1A2 mRNA,affects^expression
GUCY1A2,rs11211840-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",1e-5,1.4219085,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GUCY1A2 mRNA",affects^cotreatment|increases^expression
HAMP,rs34805185-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-6,0.83343464,Mercury,[HAMP protein results in decreased expression of SLC11A2 mRNA] which results in decreased uptake of Mercury,decreases^expression|decreases^uptake
HBB,rs12295158-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,1.5522414,Lead,HBB protein binds to Lead,affects^binding
HBEGF,rs11168036-T,Alzheimer's disease,7e-9,1.08,Lead,Lead affects the expression of HBEGF mRNA,affects^expression
HBEGF,rs11168036-T,Alzheimer's disease,7e-9,1.08,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HBEGF mRNA",affects^cotreatment|increases^expression
HBEGF,rs11168036-T,Alzheimer's disease,7e-9,1.08,lead acetate,lead acetate results in increased expression of HBEGF mRNA,increases^expression
HBEGF,rs11168036-T,Alzheimer's disease,7e-9,1.08,methylmercuric chloride,methylmercuric chloride results in increased expression of HBEGF mRNA,increases^expression
HBG2,rs113744604-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.610547,methylmercuric chloride,methylmercuric chloride results in increased expression of HBG2 mRNA,increases^expression
HDAC9,rs78872508-C,Alzheimer's disease with multiple cognitive domain impairments,2e-6,2.2222223,methylmercuric chloride,methylmercuric chloride results in decreased expression of HDAC9 mRNA,decreases^expression
HLA-C,rs17197839-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),6e-34,0.76,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-C mRNA",affects^cotreatment|increases^expression
HLA-C,rs17197839-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),6e-34,0.76,methylmercuric chloride,methylmercuric chloride results in increased expression of HLA-C mRNA,increases^expression
HLA-DQA1,rs6605556-G,Alzheimer's disease,7e-20,0.91,Mercury,Mercury results in decreased expression of HLA-DQA1 mRNA,decreases^expression
HLA-DRB1,rs6605556-G,Alzheimer's disease,7e-20,0.91,Lead,Lead affects the expression of HLA-DRB1 mRNA,affects^expression
HPCAL1,rs6735399-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,1.1613696,Lead,Lead affects the expression of HPCAL1 mRNA,affects^expression
HS3ST1,rs6448799-T,Alzheimer's disease (late onset),7e-8,1.08,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST1 mRNA",affects^cotreatment|increases^expression
HS3ST1,rs6448799-T,Alzheimer's disease (late onset),7e-8,1.08,mercuric bromide,mercuric bromide results in increased expression of HS3ST1 mRNA,increases^expression
HS3ST5,rs785129-T,Alzheimer's disease,2e-9,1.04,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HS3ST5 mRNA",affects^cotreatment|increases^expression
HSD17B4,rs115676724-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",4e-6,1.3537791,Lead,Lead results in decreased expression of HSD17B4 mRNA,decreases^expression
ICE1,rs57288781-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.3521556,Lead,Lead affects the methylation of ICE1 gene,affects^methylation
IDUA,rs3822030-G,Alzheimer's disease,8e-12,0.95,Lead,Lead affects the expression of IDUA mRNA,affects^expression
IFT81,rs144176864-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-7,0.7346949,methylmercuric chloride,methylmercuric chloride results in decreased expression of IFT81 mRNA,decreases^expression
IGF1,rs139807087-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,1.761208,Lead,Lead inhibits the reaction [IGF1 protein results in increased activity of MTR protein],decreases^reaction|increases^activity
IGF1,rs139807087-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,1.761208,Mercury,Mercury inhibits the reaction [IGF1 protein results in increased activity of MTR protein],decreases^reaction|increases^activity
IGF1,rs139807087-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,1.761208,methylmercuric chloride,methylmercuric chloride results in increased expression of IGF1 mRNA,increases^expression
IGF2BP2,rs367572673-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.5382135,Lead,Lead affects the methylation of IGF2BP2 gene,affects^methylation
IGF2R,rs9456478-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",4e-6,1.1805731,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGF2R mRNA",affects^cotreatment|increases^expression
IGHG1,rs7157106-A,Alzheimer's disease,2e-8,1.05,Lead,Lead results in decreased expression of IGHG1 mRNA,decreases^expression
IGSF11,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,Lead,Lead affects the expression of IGSF11 mRNA,affects^expression
IGSF11,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGSF11 mRNA",affects^cotreatment|increases^expression
IGSF11,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,methylmercuric chloride,methylmercuric chloride results in decreased expression of IGSF11 mRNA,decreases^expression
IL1R1,rs55735886-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-6,0.81009805,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL1R1 mRNA",affects^cotreatment|increases^expression
IL1RAP,rs7626071-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-6,1.1625315,Lead,Lead affects the expression of IL1RAP mRNA,affects^expression
IL1RAP,rs7626071-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-6,1.1625315,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA",affects^cotreatment|decreases^expression
IL1RAP,rs7626071-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-6,1.1625315,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAP mRNA",affects^cotreatment|decreases^expression
IL1RAP,rs7626071-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",9e-6,1.1625315,methylmercuric chloride,methylmercuric chloride results in decreased expression of IL1RAP mRNA,decreases^expression
IL34,rs12598456-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),3e-21,1.16,Lead,Lead affects the expression of IL34 mRNA,affects^expression
IL7R,rs114604666-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,0.7025772,lead acetate,lead acetate results in decreased expression of IL7R mRNA,decreases^expression
IMMP2L,rs59406683-A,Alzheimer's disease in APOE e4+ carriers,6e-6,1.2048193,methylmercuric chloride,methylmercuric chloride results in decreased expression of IMMP2L mRNA,decreases^expression
IMPA2,rs150315631-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.253701,methylmercuric chloride,methylmercuric chloride results in increased expression of IMPA2 mRNA,increases^expression
INPP4B,rs144453104-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,1.9228337,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA",affects^cotreatment|increases^expression
INPP5D,rs10933431-G,Alzheimer's disease,1e-18,0.92,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA",affects^cotreatment|increases^expression
INPP5D,rs10933431-G,Alzheimer's disease,1e-18,0.92,mercuric bromide,mercuric bromide results in increased expression of INPP5D mRNA,increases^expression
INPP5D,rs10933431-G,Alzheimer's disease,1e-18,0.92,methylmercuric chloride,methylmercuric chloride results in increased expression of INPP5D mRNA,increases^expression
IPO7,rs58956854-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-6,1.5108917,lead acetate,lead acetate results in decreased expression of IPO7 mRNA,decreases^expression
IQCK,rs7185636-T,Alzheimer's disease (late onset),2e-8,1.0869565,methylmercuric chloride,methylmercuric chloride results in decreased expression of IQCK mRNA,decreases^expression
IRF6,rs59043219-A,Alzheimer's disease (APOE e4 interaction),9e-6,1.19,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA",affects^cotreatment|increases^expression
IRF6,rs59043219-A,Alzheimer's disease (APOE e4 interaction),9e-6,1.19,lead acetate,lead acetate results in decreased expression of IRF6 mRNA,decreases^expression
ITGB1BP1,rs10169262-T,Alzheimer's disease,5e-8,0.95,Lead,Lead results in increased expression of ITGB1BP1 mRNA,increases^expression
ITGB8,rs10276489-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 3),6e-6,1.438,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGB8 mRNA",affects^cotreatment|increases^expression
ITGB8,rs10276489-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 3),6e-6,1.438,methylmercuric chloride,methylmercuric chloride results in increased expression of ITGB8 mRNA,increases^expression
JAZF1,rs1160871-G,Alzheimer's disease,1e-8,0.95,Lead,Lead affects the expression of JAZF1 mRNA,affects^expression
JAZF1,rs1160871-G,Alzheimer's disease,1e-8,0.95,mercuric bromide,mercuric bromide results in decreased expression of JAZF1 mRNA,decreases^expression
JAZF1,rs1160871-G,Alzheimer's disease,1e-8,0.95,methylmercuric chloride,methylmercuric chloride results in decreased expression of JAZF1 mRNA,decreases^expression
JHY,rs73606718-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 3),2e-6,3.531,methylmercuric chloride,methylmercuric chloride results in decreased expression of JHY mRNA,decreases^expression
KAT6A,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,Mercuric Chloride,Mercuric Chloride results in decreased expression of KAT6A mRNA,decreases^expression
KAT6A,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA",affects^cotreatment|decreases^expression
KAT6A,rs72640376-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,0.70878714,mercuric bromide,mercuric bromide results in decreased expression of KAT6A mRNA,decreases^expression
KCNE2,rs34532322-A,Alzheimer's disease,1e-6,1.59,Methylmercury Compounds,Methylmercury Compounds results in increased expression of KCNE2 mRNA,increases^expression
KCNJ4,rs35607824-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",9e-6,1.4694674,Lead,Lead affects the expression of KCNJ4 mRNA,affects^expression
KCNJ4,rs35607824-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",9e-6,1.4694674,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ4 mRNA",affects^cotreatment|decreases^expression
KCNN2,rs75819095-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,0.64358574,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN2 mRNA",affects^cotreatment|decreases^expression
KCNN2,rs75819095-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",9e-6,0.64358574,methylmercuric chloride,methylmercuric chloride results in increased expression of KCNN2 mRNA,increases^expression
KCNN3,rs16830122-A,Alzheimer's disease in APOE e4- carriers,2e-6,1.17,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA",affects^cotreatment|decreases^expression
KCNN3,rs16830122-A,Alzheimer's disease in APOE e4- carriers,2e-6,1.17,methylmercuric chloride,methylmercuric chloride results in decreased expression of KCNN3 mRNA,decreases^expression
KDM4B,rs536700624-?,Alzheimer's disease in non-APOE e4 carriers,8e-6,6.016,methylmercuric chloride,methylmercuric chloride results in decreased expression of KDM4B mRNA,decreases^expression
KHSRP,rs192565310-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-7,0.70730025,Lead,Lead results in decreased expression of KHSRP mRNA,decreases^expression
KHSRP,rs192565310-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-7,0.70730025,methylmercuric chloride,methylmercuric chloride results in increased expression of KHSRP mRNA,increases^expression
KIAA0232,rs10222981-T,Alzheimer's disease with language domain impairment,1e-6,2.06,methylmercuric chloride,methylmercuric chloride results in decreased expression of KIAA0232 mRNA,decreases^expression
KLF16,rs149080927-G,Alzheimer's disease,5e-10,1.05,lead acetate,lead acetate results in increased expression of KLF16 mRNA,increases^expression
KLF6,rs114394677-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.8268625,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA",affects^cotreatment|increases^expression
KLF6,rs114394677-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.8268625,mercuric bromide,mercuric bromide results in increased expression of KLF6 mRNA,increases^expression
KLF6,rs114394677-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.8268625,methylmercuric chloride,methylmercuric chloride results in increased expression of KLF6 mRNA,increases^expression
KLHL28,rs113165260-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",7e-6,0.77290434,Mercuric Chloride,Mercuric Chloride results in decreased expression of KLHL28 mRNA,decreases^expression
KLHL28,rs113165260-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",7e-6,0.77290434,methylmercuric chloride,methylmercuric chloride results in decreased expression of KLHL28 mRNA,decreases^expression
KLHL4,rs5969117-C,Alzheimer's disease,1e-6,1.490488,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA",affects^cotreatment|increases^expression
KLHL4,rs5969117-C,Alzheimer's disease,1e-6,1.490488,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLHL4 mRNA",affects^cotreatment|increases^expression
LARP6,rs75846809-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.910949,Lead,Lead affects the expression of LARP6 mRNA,affects^expression
LARP6,rs75846809-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.910949,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LARP6 mRNA",affects^cotreatment|increases^expression
LCP1,rs7338612-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 1),1e-6,1.994,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCP1 mRNA",affects^cotreatment|increases^expression
LHX9,rs142878294-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.71333796,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX9 mRNA",affects^cotreatment|decreases^expression
LIN9,rs139586416-CCT,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-7,0.6112801,Lead,Lead affects the expression of LIN9 mRNA,affects^expression
LINC01234,rs111486601-T,Alzheimer's disease (adjusted for APOE e4 dosage),1e-9,0.57,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LINC01234 mRNA",affects^cotreatment|decreases^expression
LINC01234,rs111486601-T,Alzheimer's disease (adjusted for APOE e4 dosage),1e-9,0.57,methylmercuric chloride,methylmercuric chloride results in decreased expression of LINC01234 mRNA,decreases^expression
LRAT,rs727153-C,Alzheimer's disease,3e-6,1.63,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRAT mRNA",affects^cotreatment|decreases^expression
LRIG1,rs2280575-?,Late-onset Alzheimer’s disease in APOEe4 non-carriers,2e-8,0.544,Lead,Lead affects the expression of LRIG1 mRNA,affects^expression
LRIG1,rs2280575-?,Late-onset Alzheimer’s disease in APOEe4 non-carriers,2e-8,0.544,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA",affects^cotreatment|decreases^expression
LRRIQ3,rs1340425-?,Posterior cortical atrophy and Alzheimer's disease,8e-6,1.63103,methylmercuric chloride,methylmercuric chloride results in decreased expression of LRRIQ3 mRNA,decreases^expression
LSAMP,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,Lead,Lead affects the expression of LSAMP mRNA,affects^expression
LSAMP,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LSAMP mRNA",affects^cotreatment|decreases^expression
LSAMP,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,mercuric bromide,mercuric bromide results in decreased expression of LSAMP mRNA,decreases^expression
LSAMP,rs1521291-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.83786356,methylmercuric chloride,methylmercuric chloride results in decreased expression of LSAMP mRNA,decreases^expression
MACROD2,rs6110969-T,Alzheimer's disease in APOE e4- carriers,3e-6,1.2,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA",affects^cotreatment|decreases^expression
MACROD2,rs6110969-T,Alzheimer's disease in APOE e4- carriers,3e-6,1.2,methylmercuric chloride,methylmercuric chloride results in decreased expression of MACROD2 mRNA,decreases^expression
MAP2K5,rs11637445-?,Posterior cortical atrophy and Alzheimer's disease,6e-6,1.4859304,methylmercuric chloride,methylmercuric chloride results in decreased expression of MAP2K5 mRNA,decreases^expression
MAP4K4,rs77657034-G,Alzheimer's disease,5e-6,6.912992,Lead,Lead affects the splicing of MAP4K4 mRNA,affects^splicing
MAP4K4,rs77657034-G,Alzheimer's disease,5e-6,6.912992,lead acetate,lead acetate results in increased expression of MAP4K4 mRNA,increases^expression
MAP4K4,rs77657034-G,Alzheimer's disease,5e-6,6.912992,mercuric bromide,mercuric bromide results in increased expression of MAP4K4 mRNA,increases^expression
MAP4K4,rs77657034-G,Alzheimer's disease,5e-6,6.912992,methylmercuric chloride,methylmercuric chloride results in increased expression of MAP4K4 mRNA,increases^expression
MAP7D3,rs5975709-C,Alzheimer's disease,1e-6,0.98,Lead,Lead results in decreased expression of MAP7D3 mRNA,decreases^expression
MARCHF1,rs76739370-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.7971599,methylmercuric chloride,methylmercuric chloride results in decreased expression of MARCHF1 mRNA,decreases^expression
MARK4,rs74846209-T,Alzheimer's disease (onset between ages 58 and 79),9e-16,1.43,Lead,Lead affects the splicing of MARK4 mRNA,affects^splicing
MARK4,rs74846209-T,Alzheimer's disease (onset between ages 58 and 79),9e-16,1.43,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARK4 mRNA",affects^cotreatment|decreases^expression
MCPH1,rs2442629-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8692713,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MCPH1 mRNA",affects^cotreatment|decreases^expression
MCPH1,rs2442629-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8692713,methylmercuric chloride,methylmercuric chloride results in decreased expression of MCPH1 mRNA,decreases^expression
MECOM,rs12636475-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3),2e-6,2.987,methylmercuric chloride,methylmercuric chloride results in decreased expression of MECOM mRNA,decreases^expression
MGMT,rs12256016-G,Alzheimer's disease,2e-14,2.02,Lead,Lead affects the methylation of MGMT gene,affects^methylation
MICAL2,rs114029559-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,1.5458903,Lead,Lead results in decreased expression of MICAL2 mRNA,decreases^expression
MID1,rs12852495-T,Alzheimer's disease,7e-6,1.24,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MID1 mRNA",affects^cotreatment|decreases^expression
MID1,rs12852495-T,Alzheimer's disease,7e-6,1.24,methylmercuric chloride,methylmercuric chloride results in decreased expression of MID1 mRNA,decreases^expression
MIR31HG,rs138281272-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-6,1.7492725,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR31HG mRNA",affects^cotreatment|increases^expression
MKLN1,rs4731788-?,Alzheimer's disease in non-APOE e4 carriers,5e-6,0.616,methylmercuric chloride,methylmercuric chloride results in decreased expression of MKLN1 mRNA,decreases^expression
MLLT3,rs56362410-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.8792377,lead acetate,[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MLLT3 mRNA,affects^cotreatment|increases^expression
MLLT3,rs56362410-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.8792377,methylmercuric chloride,methylmercuric chloride results in decreased expression of MLLT3 mRNA,decreases^expression
MLPH,rs10177231-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,6.513,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLPH mRNA",affects^cotreatment|increases^expression
MLPH,rs10177231-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,6.513,lead acetate,lead acetate results in increased expression of MLPH mRNA,increases^expression
MME,rs61762319-G,Alzheimer's disease,2e-11,1.16,Lead,Lead affects the folding of MME protein,affects^folding
MME,rs61762319-G,Alzheimer's disease,2e-11,1.16,Mercury,Mercury affects the folding of and results in decreased activity of MME protein,affects^folding|decreases^activity
MME,rs61762319-G,Alzheimer's disease,2e-11,1.16,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MME mRNA",affects^cotreatment|increases^expression
MMP3,rs12808148-?,Alzheimer's disease,1e-6,1.23,lead acetate,[sodium arsenite co-treated with lead acetate] results in increased expression of MMP3 protein,affects^cotreatment|increases^expression
MOB3B,rs117770454-?,Alzheimer's disease in APOE e4+ carriers,2e-6,2.844,methylmercuric chloride,methylmercuric chloride results in decreased expression of MOB3B mRNA,decreases^expression
MOB3C,rs77694075-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",6e-6,1.3609731,methylmercuric chloride,methylmercuric chloride results in increased expression of MOB3C mRNA,increases^expression
MPP7,rs11006923-?,Psychosis and Alzheimer's disease,9e-6,1.5873016,methylmercuric chloride,methylmercuric chloride results in decreased expression of MPP7 mRNA,decreases^expression
MRC1,rs4748424-G,Alzheimer's disease,3e-9,0.682,Lead,[Lead co-treated with amyloid beta-protein (1-40) co-treated with amyloid beta-protein (25-35)] results in decreased expression of MRC1 mRNA,affects^cotreatment|decreases^expression
MROH1,rs77501143-T,Alzheimer's disease,2e-6,1.11,Lead,Lead affects the expression of MROH1 mRNA,affects^expression
MROH1,rs77501143-T,Alzheimer's disease,2e-6,1.11,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MROH1 mRNA",affects^cotreatment|increases^expression
MROH1,rs77501143-T,Alzheimer's disease,2e-6,1.11,methylmercuric chloride,methylmercuric chloride results in decreased expression of MROH1 mRNA,decreases^expression
MSX2,rs10061074-?,Posterior cortical atrophy and Alzheimer's disease,7e-6,2.73556,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA",affects^cotreatment|increases^expression
MSX2,rs10061074-?,Posterior cortical atrophy and Alzheimer's disease,7e-6,2.73556,mercuric bromide,mercuric bromide results in increased expression of MSX2 mRNA,increases^expression
MSX2,rs10061074-?,Posterior cortical atrophy and Alzheimer's disease,7e-6,2.73556,methylmercuric chloride,methylmercuric chloride results in increased expression of MSX2 mRNA,increases^expression
MTHFD1L,rs11754661-A,Alzheimer's disease (late onset),2e-10,2.1,methylmercuric chloride,methylmercuric chloride results in increased expression of MTHFD1L mRNA,increases^expression
MTM1,rs146964414-T,Alzheimer's disease,8e-8,1.05,methylmercuric chloride,methylmercuric chloride results in decreased expression of MTM1 mRNA,decreases^expression
MTMR14,rs4684648-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),1e-6,2.822,Lead,Lead results in decreased expression of MTMR14 mRNA,decreases^expression
MYO16,rs912322-A,Alzheimer's disease,1e-6,1.259729,Lead,Lead affects the expression of MYO16 mRNA,affects^expression
MYO1E,rs7180978-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.86692744,Lead,Lead results in decreased expression of MYO1E mRNA,decreases^expression
MYT1L,rs2668811-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,1.5309677,methylmercuric chloride,methylmercuric chloride results in increased expression of MYT1L mRNA,increases^expression
NAV2,rs58906355-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-7,1.5548825,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAV2 mRNA",affects^cotreatment|increases^expression
NAV2,rs58906355-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-7,1.5548825,methylmercuric chloride,methylmercuric chloride results in increased expression of NAV2 mRNA,increases^expression
NBAS,rs147929195-?,Alzheimer's disease in non-APOE e4 carriers,5e-6,2.895,Lead,Lead results in decreased expression of NBAS mRNA,decreases^expression
NDST4,rs72906927-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,1.3133748,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDST4 mRNA",affects^cotreatment|increases^expression
NDST4,rs72906927-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,1.3133748,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NDST4 mRNA",affects^cotreatment|increases^expression
NEGR1,rs190217640-?,Alzheimer's disease (late onset),7e-6,1.4492754,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEGR1 mRNA",affects^cotreatment|decreases^expression
NFIC,rs9749589-T,Alzheimer's disease (APOE e4 interaction),2e-8,1.3157895,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NFIC mRNA",affects^cotreatment|decreases^expression
NFIL3,rs62562580-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",2e-6,1.3160042,lead acetate,lead acetate results in decreased expression of NFIL3 mRNA,decreases^expression
NKAIN3,rs149580982-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.48568258,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NKAIN3 mRNA",affects^cotreatment|decreases^expression
NKAIN3,rs149580982-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.48568258,mercuric bromide,mercuric bromide results in decreased expression of NKAIN3 mRNA,decreases^expression
NKAIN3,rs149580982-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.48568258,methylmercuric chloride,methylmercuric chloride results in decreased expression of NKAIN3 mRNA,decreases^expression
NKX2-6,rs17089546-A,Alzheimer's disease with multiple cognitive domain impairments,3e-6,1.86,Lead,Lead affects the methylation of NKX2-6 gene,affects^methylation
NME8,rs6966331-T,Alzheimer's disease,5e-10,0.96,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA",affects^cotreatment|increases^expression
NME8,rs6966331-T,Alzheimer's disease,5e-10,0.96,mercuric bromide,mercuric bromide results in increased expression of NME8 mRNA,increases^expression
NME8,rs6966331-T,Alzheimer's disease,5e-10,0.96,methylmercuric chloride,methylmercuric chloride results in increased expression of NME8 mRNA,increases^expression
NMRAL2P,rs9290830-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",8e-6,0.8694452,lead acetate,lead acetate results in increased expression of NMRAL2P mRNA,increases^expression
NOS1,rs11068410-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,1.3598849,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOS1 mRNA",affects^cotreatment|decreases^expression
NOS1,rs11068410-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,1.3598849,lead chloride,lead chloride results in decreased expression of NOS1 mRNA,decreases^expression
NOVA2,rs9789319-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),2e-18,1.14,Phenylmercuric Acetate,Phenylmercuric Acetate results in decreased expression of NOVA2 mRNA,decreases^expression
NOVA2,rs9789319-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),2e-18,1.14,methylmercuric chloride,methylmercuric chloride results in decreased expression of NOVA2 mRNA,decreases^expression
NPAS3,rs79709644-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.6375644,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPAS3 mRNA",affects^cotreatment|increases^expression
NPAS3,rs79709644-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.6375644,methylmercuric chloride,methylmercuric chloride results in increased expression of NPAS3 mRNA,increases^expression
NPR3,rs113892311-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.7435643,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPR3 mRNA",affects^cotreatment|increases^expression
NRG1,rs73588391-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,1.4253252,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG1 mRNA",affects^cotreatment|decreases^expression
NRG1,rs73588391-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,1.4253252,methylmercuric chloride,methylmercuric chloride results in decreased expression of NRG1 mRNA,decreases^expression
NRXN1,rs698842-A,Alzheimer's disease with multiple cognitive domain impairments,2e-6,1.96,Lead,Lead affects the splicing of NRXN1 mRNA,affects^splicing
NRXN1,rs698842-A,Alzheimer's disease with multiple cognitive domain impairments,2e-6,1.96,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN1 mRNA",affects^cotreatment|decreases^expression
NRXN1,rs698842-A,Alzheimer's disease with multiple cognitive domain impairments,2e-6,1.96,methylmercuric chloride,methylmercuric chloride results in decreased expression of NRXN1 mRNA,decreases^expression
NRXN3,rs76560721-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-7,0.6780054,Lead,Lead affects the expression of NRXN3 mRNA,affects^expression
NRXN3,rs76560721-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-7,0.6780054,mercuric bromide,mercuric bromide results in decreased expression of NRXN3 mRNA,decreases^expression
NRXN3,rs76560721-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-7,0.6780054,methylmercuric chloride,methylmercuric chloride results in decreased expression of NRXN3 mRNA,decreases^expression
NSUN2,rs149689599-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-6,1.6202817,Lead,Lead affects the expression of NSUN2 mRNA,affects^expression
NSUN2,rs149689599-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-6,1.6202817,lead acetate,[sodium arsenite co-treated with lead acetate] results in decreased expression of NSUN2 protein,affects^cotreatment|decreases^expression
NTRK3,rs74536859-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 2),1e-6,2.928,Mercury,Mercury results in increased expression of NTRK3 mRNA,increases^expression
NTRK3,rs74536859-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 2),1e-6,2.928,methylmercuric chloride,methylmercuric chloride results in decreased expression of NTRK3 mRNA,decreases^expression
NUDT12,rs13161859-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 1),3e-7,1.816,methylmercuric chloride,methylmercuric chloride results in decreased expression of NUDT12 mRNA,decreases^expression
NXN,rs2457270-C,Alzheimer's disease,5e-8,2.39,Lead,Lead affects the expression of NXN mRNA,affects^expression
OARD1,rs114812713-C,Alzheimer's disease (late onset),2e-13,1.32,methylmercuric chloride,methylmercuric chloride results in decreased expression of OARD1 mRNA,decreases^expression
OLFM1,rs11103626-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.6712971,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OLFM1 mRNA",affects^cotreatment|decreases^expression
OLFM1,rs11103626-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.6712971,methylmercuric chloride,methylmercuric chloride results in increased expression of OLFM1 mRNA,increases^expression
ONECUT2,rs60299126-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,0.7649078,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ONECUT2 mRNA",affects^cotreatment|increases^expression
ONECUT2,rs60299126-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,0.7649078,mercuric bromide,mercuric bromide results in increased expression of ONECUT2 mRNA,increases^expression
OPCML,rs543805552-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",2e-6,0.54700357,Lead,Lead affects the expression of OPCML mRNA,affects^expression
ORM1,rs116516483-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.7875724,Lead,ORM1 protein binds to Lead,affects^binding
ORM1,rs116516483-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.7875724,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ORM1 mRNA",affects^cotreatment|decreases^expression
ORM2,rs116516483-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.7875724,Lead,ORM2 protein binds to Lead,affects^binding
ORM2,rs116516483-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.7875724,Phenylmercuric Acetate,Phenylmercuric Acetate results in decreased expression of ORM2 mRNA,decreases^expression
ORM2,rs116516483-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.7875724,methylmercuric chloride,methylmercuric chloride results in increased expression of ORM2 mRNA,increases^expression
OVOL2,rs7264688-T,Alzheimer's disease with no specific cognitive domain impairment,5e-6,1.47,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OVOL2 mRNA",affects^cotreatment|increases^expression
OVOL2,rs7264688-T,Alzheimer's disease with no specific cognitive domain impairment,5e-6,1.47,mercuric bromide,mercuric bromide results in increased expression of OVOL2 mRNA,increases^expression
OVOL2,rs7264688-T,Alzheimer's disease with no specific cognitive domain impairment,5e-6,1.47,methylmercuric chloride,methylmercuric chloride results in decreased expression of OVOL2 mRNA,decreases^expression
PACS2,rs10134192-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,1.3598849,Lead,Lead results in increased expression of PACS2 mRNA,increases^expression
PACS2,rs10134192-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,1.3598849,methylmercuric chloride,methylmercuric chloride results in decreased expression of PACS2 mRNA,decreases^expression
PAK1,rs10899384-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 1),7e-7,2.183,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK1 mRNA",affects^cotreatment|decreases^expression
PAK1,rs10899384-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 1),7e-7,2.183,methylmercuric chloride,methylmercuric chloride results in decreased expression of PAK1 mRNA,decreases^expression
PAK5,rs190875284-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",9e-6,1.6691258,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PAK5 mRNA",affects^cotreatment|decreases^expression
PAK5,rs190875284-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",9e-6,1.6691258,methylmercuric chloride,methylmercuric chloride results in decreased expression of PAK5 mRNA,decreases^expression
PAX3,rs188995929-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,9.42,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA",affects^cotreatment|increases^expression
PAX3,rs188995929-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,9.42,methylmercuric chloride,methylmercuric chloride results in decreased expression of PAX3 mRNA,decreases^expression
PBX1,rs116656933-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,1.7872891,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PBX1 mRNA",affects^cotreatment|decreases^expression
PBX1,rs116656933-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,1.7872891,methylmercuric chloride,methylmercuric chloride results in decreased expression of PBX1 mRNA,decreases^expression
PCDH7,rs6856768-?,Alzheimer's disease,5e-6,1.18,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH7 mRNA",affects^cotreatment|increases^expression
PCDH7,rs6856768-?,Alzheimer's disease,5e-6,1.18,methylmercuric chloride,methylmercuric chloride results in decreased expression of PCDH7 mRNA,decreases^expression
PCSK5,rs7022215-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,1.1960207,methylmercuric chloride,methylmercuric chloride results in decreased expression of PCSK5 mRNA,decreases^expression
PDE10A,rs78375762-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.68461406,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA",affects^cotreatment|decreases^expression
PDE10A,rs78375762-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.68461406,mercuric bromide,mercuric bromide results in decreased expression of PDE10A mRNA,decreases^expression
PDE1A,rs17366218-A,Alzheimer's disease in APOE e4+ carriers,2e-6,1.5384616,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE1A mRNA",affects^cotreatment|increases^expression
PDE1A,rs17366218-A,Alzheimer's disease in APOE e4+ carriers,2e-6,1.5384616,methylmercuric chloride,methylmercuric chloride results in increased expression of PDE1A mRNA,increases^expression
PDZD2,rs397963019-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.8488269,methylmercuric chloride,methylmercuric chloride results in decreased expression of PDZD2 mRNA,decreases^expression
PEX6,rs1129187-T,Alzheimer's disease in APOE e4+ carriers,7e-6,1.13,Lead,Lead affects the expression of PEX6 mRNA,affects^expression
PHACTR2,rs147392381-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",9e-7,1.7270246,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHACTR2 mRNA",affects^cotreatment|increases^expression
PHACTR2,rs147392381-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",9e-7,1.7270246,methylmercuric chloride,methylmercuric chloride results in increased expression of PHACTR2 mRNA,increases^expression
PICALM,rs1898895-C,Alzheimer's disease,1e-14,0.89,methylmercuric chloride,methylmercuric chloride results in increased expression of PICALM mRNA,increases^expression
PIK3AP1,rs141081778-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.52782,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIK3AP1 mRNA",affects^cotreatment|decreases^expression
PIK3R1,rs115207223-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,1.7093275000000001,Lead,Lead affects the expression of PIK3R1 mRNA,affects^expression
PIP4K2A,rs560148588-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.57689214,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIP4K2A mRNA",affects^cotreatment|decreases^expression
PIP4K2A,rs560148588-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.57689214,mercuric bromide,mercuric bromide results in decreased expression of PIP4K2A mRNA,decreases^expression
PKNOX2,rs11601321-?,Alzheimer's disease (survival time),8e-6,1.63,mercuric bromide,mercuric bromide results in decreased expression of PKNOX2 mRNA,decreases^expression
PKNOX2,rs11601321-?,Alzheimer's disease (survival time),8e-6,1.63,methylmercuric chloride,methylmercuric chloride results in decreased expression of PKNOX2 mRNA,decreases^expression
PLCG2,rs12446759-G,Alzheimer's disease,1e-13,0.95,methylmercury II,methylmercury II results in decreased expression of PLCG2 mRNA,decreases^expression
PLEC,rs35139934-A,Alzheimer's disease,3e-8,1.1,Lead,Lead affects the expression of PLEC mRNA,affects^expression
PLEC,rs35139934-A,Alzheimer's disease,3e-8,1.1,lead acetate,lead acetate results in increased expression of PLEC mRNA,increases^expression
PNMA1,rs12587545-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,1.1951839,Mercury,Mercury results in decreased expression of PNMA1 mRNA,decreases^expression
POLR3B,rs11610873-C,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),3e-7,0.75,Lead,Lead results in increased expression of POLR3B mRNA,increases^expression
POLR3B,rs11610873-C,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),3e-7,0.75,methylmercuric chloride,methylmercuric chloride results in decreased expression of POLR3B mRNA,decreases^expression
PPIL2,rs1669114-?,Alzheimer's disease in APOE e4+ carriers,6e-6,0.4237,mercuric bromide,mercuric bromide results in decreased expression of PPIL2 mRNA,decreases^expression
PPIL2,rs1669114-?,Alzheimer's disease in APOE e4+ carriers,6e-6,0.4237,methylmercuric chloride,methylmercuric chloride results in decreased expression of PPIL2 mRNA,decreases^expression
PPM1L,rs141026035-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",7e-6,1.8135749,methylmercuric chloride,methylmercuric chloride results in decreased expression of PPM1L mRNA,decreases^expression
PPP1R3B,rs3748140-?,Alzheimer's disease,3e-7,2.43,methylmercuric chloride,methylmercuric chloride results in decreased expression of PPP1R3B mRNA,decreases^expression
PREX2,rs28524839-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.7899721,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PREX2 mRNA",affects^cotreatment|decreases^expression
PREX2,rs28524839-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.7899721,methylmercuric chloride,methylmercuric chloride results in decreased expression of PREX2 mRNA,decreases^expression
PRICKLE1,rs896559-C,Alzheimer's disease,8e-10,2.44,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRICKLE1 mRNA",affects^cotreatment|increases^expression
PRICKLE2,rs143785410-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,1.4172239,Lead,Lead affects the expression of PRICKLE2 mRNA,affects^expression
PRICKLE2,rs143785410-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,1.4172239,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRICKLE2 mRNA",affects^cotreatment|increases^expression
PRIM2,rs6904307-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),6e-21,1.24,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRIM2 mRNA",affects^cotreatment|decreases^expression
PRKAG2,rs79439364-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.7235739,Lead,Lead affects the expression of PRKAG2 mRNA,affects^expression
PRKAG2,rs79439364-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.7235739,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKAG2 mRNA",affects^cotreatment|increases^expression
PRKAG2,rs79439364-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.7235739,methylmercuric chloride,methylmercuric chloride results in increased expression of PRKAG2 mRNA,increases^expression
PRKCH,rs139149613-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,0.6143442,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKCH mRNA",affects^cotreatment|increases^expression
PRKCH,rs139149613-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,0.6143442,mercuric bromide,mercuric bromide results in increased expression of PRKCH mRNA,increases^expression
PRKG1,rs150783484-?,Alzheimer's disease in non-APOE e4 carriers,2e-6,3.494,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRKG1 mRNA",affects^cotreatment|decreases^expression
PRKG1,rs150783484-?,Alzheimer's disease in non-APOE e4 carriers,2e-6,3.494,methylmercuric chloride,methylmercuric chloride results in decreased expression of PRKG1 mRNA,decreases^expression
PRKN,rs139539873-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.5404247,Lead,[[amyloid beta-protein (25-35) co-treated with amyloid beta-protein (1-40)] co-treated with [lead acetate results in increased abundance of Lead]] results in decreased expression of PRKN protein,affects^cotreatment|decreases^expression|increases^abundance
PRKN,rs139539873-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.5404247,lead acetate,[[amyloid beta-protein (25-35) co-treated with amyloid beta-protein (1-40)] co-treated with [lead acetate results in increased abundance of Lead]] results in decreased expression of PRKN protein,affects^cotreatment|decreases^expression|increases^abundance
PRRX1,rs59597570-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-6,1.108824,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRRX1 mRNA",affects^cotreatment|decreases^expression
PRRX1,rs59597570-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-6,1.108824,methylmercuric chloride,methylmercuric chloride results in decreased expression of PRRX1 mRNA,decreases^expression
PTGDR,rs566835324-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.54694885,methylmercuric chloride,methylmercuric chloride results in decreased expression of PTGDR mRNA,decreases^expression
PTK2B,rs73223431-T,Alzheimer's disease,4e-22,1.07,Lead,Lead results in decreased expression of PTK2B mRNA,decreases^expression
PTN,rs73452975-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,1.6549983,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTN mRNA",affects^cotreatment|decreases^expression
PTN,rs73452975-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,1.6549983,methylmercuric chloride,methylmercuric chloride results in increased expression of PTN mRNA,increases^expression
PTPRM,rs113300914-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,1.2602372,Lead,Lead affects the expression of PTPRM mRNA,affects^expression
PTPRM,rs113300914-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,1.2602372,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PTPRM mRNA",affects^cotreatment|increases^expression
PTPRS,rs10405017-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.1474017,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PTPRS mRNA",affects^cotreatment|decreases^expression
PUF60,rs11782759-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",3e-6,0.8032414,Lead,Lead affects the splicing of PUF60 mRNA,affects^splicing
PURPL,rs72746279-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 1),4e-6,2.234,methylmercuric chloride,methylmercuric chloride results in decreased expression of PURPL mRNA,decreases^expression
PWWP2A,rs562024322-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,0.6228809,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PWWP2A mRNA",affects^cotreatment|decreases^expression
QKI,rs6924130-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 3),4e-6,2.031,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA",affects^cotreatment|increases^expression
RAB23,rs6904307-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),6e-21,1.24,methylmercuric chloride,methylmercuric chloride results in decreased expression of RAB23 mRNA,decreases^expression
RAB31,rs6506688-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs clinical) (case-control set 1),1e-5,0.3217,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB31 mRNA",affects^cotreatment|increases^expression
RAB31,rs6506688-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs clinical) (case-control set 1),1e-5,0.3217,methylmercuric chloride,methylmercuric chloride results in increased expression of RAB31 mRNA,increases^expression
RAMP1,rs56396048-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",7e-6,1.1960207,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAMP1 mRNA",affects^cotreatment|increases^expression
RAPGEF6,rs6890695-G,Alzheimer's disease in APOE e4- carriers,6e-7,1.1494253,Lead,Lead affects the expression of RAPGEF6 mRNA,affects^expression
RASEF,rs7035907-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.172807,Lead,Lead results in increased expression of RASEF mRNA,increases^expression
RASEF,rs7035907-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.172807,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA",affects^cotreatment|increases^expression
RASEF,rs7035907-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.172807,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RASEF mRNA",affects^cotreatment|increases^expression
RASEF,rs7035907-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",5e-6,1.172807,methylmercuric chloride,methylmercuric chloride results in increased expression of RASEF mRNA,increases^expression
RASGEF1C,rs113706587-A,Alzheimer's disease,2e-16,1.09,Lead,Lead affects the expression of RASGEF1C mRNA,affects^expression
RASGEF1C,rs113706587-A,Alzheimer's disease,2e-16,1.09,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASGEF1C mRNA",affects^cotreatment|decreases^expression
RASSF10,rs143902215-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,1.8430098,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RASSF10 mRNA",affects^cotreatment|decreases^expression
RASSF10,rs143902215-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,1.8430098,methylmercuric chloride,methylmercuric chloride results in decreased expression of RASSF10 mRNA,decreases^expression
RBFOX1,rs79537509-?,Alzheimer's disease,5e-7,4.61,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBFOX1 mRNA",affects^cotreatment|increases^expression
RBFOX3,rs4789973-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,1.2934331,Lead,Lead affects the expression of RBFOX3 mRNA,affects^expression
RBFOX3,rs4789973-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,1.2934331,Mercury,"[diethyl phosphate co-treated with Cotinine co-treated with bis(2,3,3,3-tetrachloropropyl) ether co-treated with Mercury co-treated with Selenium] results in increased expression of RBFOX3 mRNA",affects^cotreatment|increases^expression
RBFOX3,rs4789973-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,1.2934331,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA",affects^cotreatment|decreases^expression
RBFOX3,rs4789973-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,1.2934331,mercuric bromide,mercuric bromide results in decreased expression of RBFOX3 mRNA,decreases^expression
RBFOX3,rs4789973-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,1.2934331,methylmercuric chloride,methylmercuric chloride results in decreased expression of RBFOX3 mRNA,decreases^expression
RBMS3,rs2221154-?,Alzheimer's disease,3e-6,1.75,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RBMS3 mRNA",affects^cotreatment|increases^expression
RBMS3,rs2221154-?,Alzheimer's disease,3e-6,1.75,mercuric bromide,mercuric bromide results in increased expression of RBMS3 mRNA,increases^expression
REN,rs6699047-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.8402129,methylmercuric chloride,methylmercuric chloride results in decreased expression of REN mRNA,decreases^expression
RFX4,rs11610873-C,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),3e-7,0.75,mercuric bromide,mercuric bromide results in decreased expression of RFX4 mRNA,decreases^expression
RFX4,rs11610873-C,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),3e-7,0.75,methylmercuric chloride,methylmercuric chloride results in decreased expression of RFX4 mRNA,decreases^expression
RGS17,rs77248137-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,1.39822,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RGS17 mRNA",affects^cotreatment|decreases^expression
RGS4,rs77869173-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,1.2350359,methylmercuric chloride,methylmercuric chloride results in decreased expression of RGS4 mRNA,decreases^expression
RHBDF1,rs78541046-?,Alzheimer's disease (late onset),2e-6,6.2228026,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHBDF1 mRNA",affects^cotreatment|increases^expression
RHOBTB3,rs116568941-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6284033,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOBTB3 mRNA",affects^cotreatment|increases^expression
RHOBTB3,rs116568941-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6284033,mercuric bromide,mercuric bromide results in increased expression of RHOBTB3 mRNA,increases^expression
RHOBTB3,rs116568941-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,1.6284033,methylmercuric chloride,methylmercuric chloride results in increased expression of RHOBTB3 mRNA,increases^expression
RHOH,rs2245466-G,Alzheimer's disease,1e-9,1.05,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RHOH mRNA",affects^cotreatment|decreases^expression
RHOH,rs2245466-G,Alzheimer's disease,1e-9,1.05,methylmercuric chloride,methylmercuric chloride results in increased expression of RHOH mRNA,increases^expression
RHPN2,rs2161225-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",8e-6,1.1529225,Lead,Lead affects the expression of RHPN2 mRNA,affects^expression
RHPN2,rs2161225-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",8e-6,1.1529225,methylmercuric chloride,methylmercuric chloride results in decreased expression of RHPN2 mRNA,decreases^expression
RIMBP2,rs12809872-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.8993347,Lead,Lead affects the expression of RIMBP2 mRNA,affects^expression
RIMBP2,rs12809872-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.8993347,methylmercuric chloride,methylmercuric chloride results in decreased expression of RIMBP2 mRNA,decreases^expression
RIMS1,rs58015227-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,1.174685,Lead,Lead affects the expression of RIMS1 mRNA,affects^expression
RNF125,rs61392417-T,Alzheimer's disease,4e-8,0.95,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF125 mRNA",affects^cotreatment|decreases^expression
RNF125,rs61392417-T,Alzheimer's disease,4e-8,0.95,mercuric bromide,mercuric bromide results in decreased expression of RNF125 mRNA,decreases^expression
RNF130,rs143255859-?,Alzheimer's disease in non-APOE e4 carriers,8e-6,3.278,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF130 mRNA",affects^cotreatment|decreases^expression
RNF130,rs143255859-?,Alzheimer's disease in non-APOE e4 carriers,8e-6,3.278,mercuric bromide,mercuric bromide results in decreased expression of RNF130 mRNA,decreases^expression
RNF130,rs143255859-?,Alzheimer's disease in non-APOE e4 carriers,8e-6,3.278,methylmercuric chloride,methylmercuric chloride results in decreased expression of RNF130 mRNA,decreases^expression
RNF220,rs56310312-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-7,1.1748024,Lead,Lead results in decreased expression of RNF220 mRNA,decreases^expression
RNF6,rs17511627-C,Alzheimer's disease,5e-6,1.75,Lead,Lead affects the expression of RNF6 mRNA,affects^expression
RNF6,rs17511627-C,Alzheimer's disease,5e-6,1.75,methylmercuric chloride,methylmercuric chloride results in increased expression of RNF6 mRNA,increases^expression
ROBO1,rs11919682-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.88674307,Lead,Lead results in increased expression of ROBO1 mRNA,increases^expression
ROBO1,rs11919682-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.88674307,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO1 mRNA",affects^cotreatment|decreases^expression
ROBO2,rs112753448-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.52908826,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA",affects^cotreatment|decreases^expression
ROBO2,rs112753448-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.52908826,methylmercuric chloride,methylmercuric chloride results in decreased expression of ROBO2 mRNA,decreases^expression
RORA,rs76633761-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.7480484,methylmercuric chloride,methylmercuric chloride results in decreased expression of RORA mRNA,decreases^expression
RPS6KA2,rs73039501-?,Alzheimer's disease in APOE e4+ carriers,1e-6,3.665,Lead,Lead affects the splicing of RPS6KA2 mRNA,affects^splicing
RPS6KA2,rs73039501-?,Alzheimer's disease in APOE e4+ carriers,1e-6,3.665,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA2 mRNA",affects^cotreatment|increases^expression
RRAGC,rs592897-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),7e-6,2.445,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RRAGC mRNA",affects^cotreatment|increases^expression
RUNX2,rs6415148-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.88444054,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA",affects^cotreatment|increases^expression
RUNX2,rs6415148-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.88444054,lead nitrate,lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA],affects^cotreatment|decreases^reaction|increases^expression
RUNX2,rs6415148-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-7,0.88444054,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX2 mRNA",affects^cotreatment|increases^expression
SBF2,rs181330831-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.6486902,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SBF2 mRNA",affects^cotreatment|increases^expression
SBF2,rs181330831-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.6486902,mercuric bromide,mercuric bromide results in increased expression of SBF2 mRNA,increases^expression
SBF2,rs181330831-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.6486902,methylmercuric chloride,methylmercuric chloride results in increased expression of SBF2 mRNA,increases^expression
SCAPER,rs2469249-?,Alzheimer’s disease polygenic risk score (upper quantile vs lower quantile),5e-23,0.85,methylmercuric chloride,methylmercuric chloride results in decreased expression of SCAPER mRNA,decreases^expression
SCARA3,rs569214-?,Alzheimer's disease,4e-8,1.14,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SCARA3 mRNA",affects^cotreatment|decreases^expression
SCARA3,rs569214-?,Alzheimer's disease,4e-8,1.14,methylmercuric chloride,methylmercuric chloride results in decreased expression of SCARA3 mRNA,decreases^expression
SCFD2,rs184984767-?,Alzheimer's disease in non-APOE e4 carriers,2e-6,5.934,methylmercuric chloride,methylmercuric chloride results in decreased expression of SCFD2 mRNA,decreases^expression
SDK1,rs36076521-A,Alzheimer's disease,4e-8,2.4,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SDK1 mRNA",affects^cotreatment|increases^expression
SDK2,rs115839552-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,1.7407221,methylmercuric chloride,methylmercuric chloride results in decreased expression of SDK2 mRNA,decreases^expression
SDR9C7,rs840163-?,Alzheimer's disease (survival time),2e-6,1.4,Lead,Lead affects the methylation of SDR9C7 gene,affects^methylation
SEMA3C,rs2525776-?,Posterior cortical atrophy and Alzheimer's disease,1e-8,3.3,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3C mRNA",affects^cotreatment|increases^expression
SEMA3C,rs2525776-?,Posterior cortical atrophy and Alzheimer's disease,1e-8,3.3,mercuric bromide,mercuric bromide results in increased expression of SEMA3C mRNA,increases^expression
SEMA5A,rs34191781-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",5e-6,0.8071062,methylmercuric chloride,methylmercuric chloride results in decreased expression of SEMA5A mRNA,decreases^expression
SENP7,rs6806784-?,Alzheimer's disease (late onset),4e-6,1.53,methylmercuric chloride,methylmercuric chloride results in decreased expression of SENP7 mRNA,decreases^expression
SERINC5,rs71636213-G,Alzheimer's disease in APOE e4- carriers,9e-6,1.18,Lead,Lead affects the expression of SERINC5 mRNA,affects^expression
SERINC5,rs71636213-G,Alzheimer's disease in APOE e4- carriers,9e-6,1.18,methylmercuric chloride,methylmercuric chloride results in decreased expression of SERINC5 mRNA,decreases^expression
SERPINE1,rs10953322-?,Alzheimer's disease,5e-6,1.3187115,Mercuric Chloride,Mercuric Chloride results in increased expression of SERPINE1 mRNA,increases^expression
SERPINE1,rs10953322-?,Alzheimer's disease,5e-6,1.3187115,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINE1 mRNA",affects^cotreatment|increases^expression
SERPINE1,rs10953322-?,Alzheimer's disease,5e-6,1.3187115,lead acetate,lead acetate results in increased expression of SERPINE1 mRNA,increases^expression
SERPINE1,rs10953322-?,Alzheimer's disease,5e-6,1.3187115,mercuric bromide,mercuric bromide results in increased expression of SERPINE1 mRNA,increases^expression
SERPINE1,rs10953322-?,Alzheimer's disease,5e-6,1.3187115,methylmercuric chloride,methylmercuric chloride results in increased expression of SERPINE1 mRNA,increases^expression
SETBP1,rs7235333-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-7,0.8558159,methylmercuric chloride,methylmercuric chloride results in decreased expression of SETBP1 mRNA,decreases^expression
SETD7,rs535347112-T,Alzheimer's disease,4e-8,2.02,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SETD7 mRNA",affects^cotreatment|increases^expression
SETD7,rs535347112-T,Alzheimer's disease,4e-8,2.02,methylmercuric chloride,methylmercuric chloride results in increased expression of SETD7 mRNA,increases^expression
SETX,rs117247154-?,Alzheimer's disease in non-APOE e4 carriers,2e-6,2.458,Mercuric Chloride,Mercuric Chloride results in decreased expression of SETX mRNA,decreases^expression
SEZ6L2,rs150987621-T,Alzheimer's disease,5e-8,1.8,Lead,Lead affects the expression of SEZ6L2 mRNA,affects^expression
SEZ6L2,rs150987621-T,Alzheimer's disease,5e-8,1.8,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEZ6L2 mRNA",affects^cotreatment|decreases^expression
SIPA1L2,rs115684722-?,Alzheimer's disease,6e-7,12.6,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SIPA1L2 mRNA",affects^cotreatment|increases^expression
SIPA1L2,rs115684722-?,Alzheimer's disease,6e-7,12.6,mercuric bromide,mercuric bromide results in increased expression of SIPA1L2 mRNA,increases^expression
SIPA1L2,rs115684722-?,Alzheimer's disease,6e-7,12.6,methylmercuric chloride,methylmercuric chloride results in increased expression of SIPA1L2 mRNA,increases^expression
SLC24A3,rs6136629-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.2248275,Lead,Lead affects the expression of SLC24A3 mRNA,affects^expression
SLC25A12,rs149366681-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",7e-6,0.6561276,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A12 mRNA",affects^cotreatment|increases^expression
SLC2A13,rs75036080-?,Alzheimer's disease in hypertension,3e-6,2.0576131,Lead,Lead affects the expression of SLC2A13 mRNA,affects^expression
SLC2A13,rs75036080-?,Alzheimer's disease in hypertension,3e-6,2.0576131,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA",affects^cotreatment|increases^expression
SLC2A4RG,rs6742-T,Alzheimer's disease,3e-9,0.95,Lead,Lead results in increased expression of SLC2A4RG mRNA,increases^expression
SLC2A4RG,rs6742-T,Alzheimer's disease,3e-9,0.95,lead acetate,lead acetate results in increased expression of SLC2A4RG mRNA,increases^expression
SLC35F3,rs510560-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.8206981,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC35F3 mRNA",affects^cotreatment|decreases^expression
SLC39A8,rs149970512-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.5104384,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA",affects^cotreatment|increases^expression
SLC39A8,rs149970512-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.5104384,lead acetate,lead acetate results in decreased expression of SLC39A8 mRNA,decreases^expression
SLC39A8,rs149970512-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.5104384,mercuric bromide,mercuric bromide results in increased expression of SLC39A8 mRNA,increases^expression
SLC39A8,rs149970512-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",2e-6,1.5104384,methylmercuric chloride,methylmercuric chloride results in increased expression of SLC39A8 mRNA,increases^expression
SLC4A1AP,rs17006206-G,Alzheimer's disease,2e-6,2.05,Lead,Lead results in increased expression of SLC4A1AP mRNA,increases^expression
SLC6A1,rs9860800-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8084795,Lead,Lead affects the expression of SLC6A1 mRNA,affects^expression
SLC6A11,rs9860800-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8084795,Lead,Lead affects the expression of SLC6A11 mRNA,affects^expression
SLC6A11,rs9860800-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,0.8084795,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC6A11 mRNA",affects^cotreatment|decreases^expression
SLC7A2,rs183994654-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.6950293,Mercury,Mercury results in decreased expression of SLC7A2 mRNA,decreases^expression
SLC7A2,rs183994654-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.6950293,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC7A2 mRNA",affects^cotreatment|increases^expression
SLC7A2,rs183994654-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.6950293,mercuric bromide,mercuric bromide results in increased expression of SLC7A2 mRNA,increases^expression
SLC7A2,rs183994654-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.6950293,methylmercuric chloride,methylmercuric chloride results in decreased expression of SLC7A2 mRNA,decreases^expression
SLC9A7,rs2142791-C,Alzheimer's disease,4e-8,1.03,Lead,Lead affects the expression of SLC9A7 mRNA,affects^expression
SLCO4A1,rs74362380-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",7e-8,1.5562825,Lead,Lead results in increased expression of SLCO4A1 mRNA,increases^expression
SLCO4A1,rs74362380-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",7e-8,1.5562825,lead acetate,lead acetate results in decreased expression of SLCO4A1 mRNA,decreases^expression
SMARCA2,rs567594870-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.653247,Lead,Lead affects the expression of SMARCA2 mRNA,affects^expression
SMARCA2,rs567594870-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.653247,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA",affects^cotreatment|increases^expression
SMARCA2,rs567594870-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.653247,lead acetate,lead acetate results in increased expression of SMARCA2 protein,increases^expression
SMARCA2,rs567594870-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.653247,mercuric bromide,mercuric bromide results in increased expression of SMARCA2 mRNA,increases^expression
SMARCA2,rs567594870-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.653247,methylmercuric chloride,methylmercuric chloride results in increased expression of SMARCA2 mRNA,increases^expression
SNX1,rs3848143-G,Alzheimer's disease,8e-11,1.05,methylmercuric chloride,methylmercuric chloride results in decreased expression of SNX1 mRNA,decreases^expression
SNX18,rs539770320-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",8e-6,1.7590959,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNX18 mRNA",affects^cotreatment|increases^expression
SOBP,rs4645455-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.1575434,Lead,Lead results in decreased expression of SOBP mRNA,decreases^expression
SOBP,rs4645455-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.1575434,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOBP mRNA",affects^cotreatment|decreases^expression
SOBP,rs4645455-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.1575434,mercuric bromide,mercuric bromide results in decreased expression of SOBP mRNA,decreases^expression
SOBP,rs4645455-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",6e-6,1.1575434,methylmercuric chloride,methylmercuric chloride results in decreased expression of SOBP mRNA,decreases^expression
SORBS2,rs76819555-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,3.815,Lead,Lead affects the expression of SORBS2 mRNA,affects^expression
SORBS2,rs76819555-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,3.815,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SORBS2 mRNA",affects^cotreatment|increases^expression
SORBS2,rs76819555-?,Alzheimer's disease in non-APOE e4 carriers,6e-6,3.815,methylmercuric chloride,methylmercuric chloride results in increased expression of SORBS2 mRNA,increases^expression
SORCS1,rs1890078-?,Alzheimer's disease in APOE e4+ carriers,7e-7,0.43,Lead,Lead affects the expression of SORCS1 mRNA,affects^expression
SORCS1,rs1890078-?,Alzheimer's disease in APOE e4+ carriers,7e-7,0.43,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA",affects^cotreatment|decreases^expression
SORCS1,rs1890078-?,Alzheimer's disease in APOE e4+ carriers,7e-7,0.43,mercuric bromide,mercuric bromide results in decreased expression of SORCS1 mRNA,decreases^expression
SORL1,rs11218343-C,Alzheimer's disease,1e-21,0.84,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORL1 mRNA",affects^cotreatment|decreases^expression
SORL1,rs11218343-C,Alzheimer's disease,1e-21,0.84,methylmercuric chloride,methylmercuric chloride results in decreased expression of SORL1 mRNA,decreases^expression
SPEF2,rs114604666-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",4e-6,0.7025772,methylmercuric chloride,methylmercuric chloride results in decreased expression of SPEF2 mRNA,decreases^expression
SPOCK3,rs143469568-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,0.6392881,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPOCK3 mRNA",affects^cotreatment|increases^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,Lead,Lead affects the expression of SPP1 mRNA,affects^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,Mercuric Chloride,Mercuric Chloride results in increased expression of SPP1 mRNA,increases^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,Mercury,Mercury results in increased expression of SPP1 mRNA,increases^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPP1 mRNA",affects^cotreatment|increases^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,lead acetate,lead acetate results in increased expression of and results in increased secretion of SPP1 protein,increases^expression|increases^secretion
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,lead chloride,lead chloride results in increased expression of SPP1 mRNA,increases^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,mercuric bromide,mercuric bromide results in increased expression of SPP1 mRNA,increases^expression
SPP1,rs2853750-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",4e-6,0.62995934,methylmercuric chloride,methylmercuric chloride results in increased expression of SPP1 mRNA,increases^expression
SPPL2A,rs8025980-G,Alzheimer's disease,1e-8,0.96,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SPPL2A mRNA",affects^cotreatment|increases^expression
SPTBN1,rs62134681-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,1.2603633,Lead,Lead affects the expression of SPTBN1 mRNA,affects^expression
SPTBN1,rs62134681-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,1.2603633,Mercury,Mercury results in increased expression of SPTBN1 mRNA,increases^expression
SPTBN1,rs62134681-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,1.2603633,lead acetate,[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SPTBN1 mRNA,affects^cotreatment|decreases^expression
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,Ethylmercury Compounds,Ethylmercury Compounds results in increased expression of SQSTM1 protein,increases^expression
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,Lead,Lead affects the expression of SQSTM1 mRNA,affects^expression
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,Methylmercury Compounds,[SQSTM1 protein affects the susceptibility to Methylmercury Compounds] which affects the expression of DDIT3 mRNA,affects^expression|affects^response to substance
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SQSTM1 mRNA",affects^cotreatment|increases^expression
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,lead acetate,"(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [lead acetate results in increased expression of SQSTM1 protein]",decreases^reaction|increases^expression
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,mercuric bromide,mercuric bromide results in increased expression of SQSTM1 mRNA,increases^expression
SQSTM1,rs72807343-T,Alzheimer's disease (late onset),7e-7,1.35,methylmercuric chloride,methylmercuric chloride results in increased expression of SQSTM1 mRNA,increases^expression
SRCIN1,rs12450778-?,Alzheimer's disease,2e-6,2.4201357,Lead,Lead affects the expression of SRCIN1 mRNA,affects^expression
SRCIN1,rs12450778-?,Alzheimer's disease,2e-6,2.4201357,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SRCIN1 mRNA",affects^cotreatment|decreases^expression
SRCIN1,rs12450778-?,Alzheimer's disease,2e-6,2.4201357,mercuric bromide,mercuric bromide results in decreased expression of SRCIN1 mRNA,decreases^expression
SRCIN1,rs12450778-?,Alzheimer's disease,2e-6,2.4201357,methylmercuric chloride,methylmercuric chloride results in decreased expression of SRCIN1 mRNA,decreases^expression
SS18,rs16941876-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,1.555038,Lead,Lead affects the expression of SS18 mRNA,affects^expression
SS18,rs16941876-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,1.555038,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SS18 mRNA",affects^cotreatment|increases^expression
STC1,rs17089546-A,Alzheimer's disease with multiple cognitive domain impairments,3e-6,1.86,lead acetate,lead acetate results in decreased expression of STC1 mRNA,decreases^expression
STC1,rs17089546-A,Alzheimer's disease with multiple cognitive domain impairments,3e-6,1.86,methylmercuric chloride,methylmercuric chloride results in decreased expression of STC1 mRNA,decreases^expression
STMN4,rs78960159-?,Rapidly progressive Alzheimer's disease (clinical) (case-control set 2),1e-5,2.274,methylmercuric chloride,methylmercuric chloride results in decreased expression of STMN4 mRNA,decreases^expression
SUPT20H,rs148128180-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",4e-6,0.5689857,methylmercuric chloride,methylmercuric chloride results in decreased expression of SUPT20H mRNA,decreases^expression
SUSD5,rs35310979-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs typical) (case-control set 2),4e-6,3.653,methylmercuric chloride,methylmercuric chloride results in decreased expression of SUSD5 mRNA,decreases^expression
SYN2,rs1355782609-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",7e-6,0.62725633,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SYN2 mRNA",affects^cotreatment|decreases^expression
SYNPR,rs116668122-T,Alzheimer's disease,2e-9,1.87,Lead,Lead affects the expression of SYNPR mRNA,affects^expression
SYNPR,rs116668122-T,Alzheimer's disease,2e-9,1.87,mercuric bromide,mercuric bromide results in increased expression of SYNPR mRNA,increases^expression
SYNPR,rs116668122-T,Alzheimer's disease,2e-9,1.87,methylmercuric chloride,methylmercuric chloride results in decreased expression of SYNPR mRNA,decreases^expression
SYNPR-AS1,rs116668122-T,Alzheimer's disease,2e-9,1.87,methylmercuric chloride,methylmercuric chloride results in decreased expression of SYNPR-AS1 mRNA,decreases^expression
SYPL1,rs6978679-A,Alzheimer's disease with no specific cognitive domain impairment,2e-6,1.36,Lead,Lead affects the expression of SYPL1 mRNA,affects^expression
TASOR2,rs9971188-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,0.8297756,Lead,Lead results in decreased expression of TASOR2 mRNA,decreases^expression
TASOR2,rs9971188-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",5e-6,0.8297756,methylmercuric chloride,methylmercuric chloride results in decreased expression of TASOR2 mRNA,decreases^expression
TENM2,rs6555748-G,Alzheimer's disease,4e-8,2.4,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENM2 mRNA",affects^cotreatment|increases^expression
TENM2,rs6555748-G,Alzheimer's disease,4e-8,2.4,methylmercuric chloride,methylmercuric chloride results in decreased expression of TENM2 mRNA,decreases^expression
TENT5A,rs72907046-?,Posterior cortical atrophy and Alzheimer's disease,1e-9,3.2,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TENT5A mRNA",affects^cotreatment|increases^expression
TENT5A,rs72907046-?,Posterior cortical atrophy and Alzheimer's disease,1e-9,3.2,methylmercuric chloride,methylmercuric chloride results in decreased expression of TENT5A mRNA,decreases^expression
TFAM,rs556906573-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",5e-6,0.6015173,methylmercuric chloride,methylmercuric chloride results in decreased expression of TFAM mRNA,decreases^expression
TGFBR3,rs2480707-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",8e-6,0.686877,methylmercuric chloride,methylmercuric chloride results in decreased expression of TGFBR3 mRNA,decreases^expression
THSD7A,rs1595014-T,Alzheimer's disease (APOE e4 interaction),4e-6,1.1904762,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THSD7A mRNA",affects^cotreatment|increases^expression
THSD7A,rs1595014-T,Alzheimer's disease (APOE e4 interaction),4e-6,1.1904762,mercuric bromide,mercuric bromide results in increased expression of THSD7A mRNA,increases^expression
THSD7A,rs1595014-T,Alzheimer's disease (APOE e4 interaction),4e-6,1.1904762,methylmercuric chloride,methylmercuric chloride results in increased expression of THSD7A mRNA,increases^expression
TLE4,rs74590434-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,0.6338772,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TLE4 mRNA",affects^cotreatment|decreases^expression
TLE4,rs74590434-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,0.6338772,methylmercuric chloride,methylmercuric chloride results in increased expression of TLE4 mRNA,increases^expression
TMEM106B,rs13237518-A,Alzheimer's disease,5e-11,0.96,Mercuric Chloride,Mercuric Chloride results in decreased expression of TMEM106B mRNA,decreases^expression
TMEM132C,rs73161924-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed) (case-control set 1),2e-6,4.026,methylmercuric chloride,methylmercuric chloride results in decreased expression of TMEM132C mRNA,decreases^expression
TMEM150C,rs183084422-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,1.5045593,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM150C mRNA",affects^cotreatment|decreases^expression
TMEM150C,rs183084422-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,1.5045593,mercuric bromide,"[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM150C mRNA",affects^cotreatment|decreases^expression
TMEM163,rs76344186-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",2e-6,0.59672433,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TMEM163 mRNA",affects^cotreatment|decreases^expression
TMEM163,rs76344186-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",2e-6,0.59672433,mercuric bromide,mercuric bromide results in decreased expression of TMEM163 mRNA,decreases^expression
TNFSF13,rs58840546-T,Alzheimer's disease,5e-8,0.92,Lead,Lead results in decreased expression of TNFSF13 mRNA,decreases^expression
TNRC6C,rs16970672-?,Psychosis and Alzheimer's disease,2e-6,1.29,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNRC6C mRNA",affects^cotreatment|decreases^expression
TNRC6C,rs16970672-?,Psychosis and Alzheimer's disease,2e-6,1.29,methylmercuric chloride,methylmercuric chloride results in decreased expression of TNRC6C mRNA,decreases^expression
TPCN2,rs10896430-?,Alzheimer's disease in non-APOE e4 carriers,2e-6,1.684,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPCN2 mRNA",affects^cotreatment|increases^expression
TPD52,rs1426149-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",2e-6,1.1703466,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TPD52 mRNA",affects^cotreatment|decreases^expression
TPD52,rs1426149-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",2e-6,1.1703466,methylmercuric chloride,methylmercuric chloride results in decreased expression of TPD52 mRNA,decreases^expression
TRA2B,rs367572673-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.5382135,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRA2B mRNA",affects^cotreatment|decreases^expression
TRA2B,rs367572673-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",2e-6,0.5382135,methylmercuric chloride,methylmercuric chloride results in decreased expression of TRA2B mRNA,decreases^expression
TRAPPC6A,rs192775394-C,Alzheimer's disease (onset between ages 58 and 79),8e-9,1.88,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRAPPC6A mRNA",affects^cotreatment|decreases^expression
TRAPPC6A,rs192775394-C,Alzheimer's disease (onset between ages 58 and 79),8e-9,1.88,mercuric bromide,mercuric bromide results in decreased expression of TRAPPC6A mRNA,decreases^expression
TRAPPC6A,rs192775394-C,Alzheimer's disease (onset between ages 58 and 79),8e-9,1.88,methylmercuric chloride,methylmercuric chloride results in decreased expression of TRAPPC6A mRNA,decreases^expression
TRH,rs34925435-?,Alzheimer's disease,5e-6,2.7270248,Lead,Lead affects the expression of TRH mRNA,affects^expression
TRH,rs34925435-?,Alzheimer's disease,5e-6,2.7270248,methylmercuric chloride,methylmercuric chloride results in decreased expression of TRH mRNA,decreases^expression
TRIB1,rs115038899-T,Alzheimer's disease,3e-8,1.08,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TRIB1 mRNA",affects^cotreatment|decreases^expression
TRIM56,rs10953322-?,Alzheimer's disease,5e-6,1.3187115,methylmercuric chloride,methylmercuric chloride results in increased expression of TRIM56 mRNA,increases^expression
TRPS1,rs75683771-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.7774779,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRPS1 mRNA",affects^cotreatment|increases^expression
TRPS1,rs75683771-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.7774779,mercuric bromide,mercuric bromide results in increased expression of TRPS1 mRNA,increases^expression
TRPS1,rs75683771-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",3e-6,0.7774779,methylmercuric chloride,methylmercuric chloride results in increased expression of TRPS1 mRNA,increases^expression
TSHZ1,rs28377869-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,1.2671877,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TSHZ1 mRNA",affects^cotreatment|increases^expression
TSHZ1,rs28377869-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",8e-6,1.2671877,methylmercuric chloride,methylmercuric chloride results in increased expression of TSHZ1 mRNA,increases^expression
TSHZ2,rs6097145-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",6e-7,1.3604289,Lead,Lead results in increased expression of TSHZ2 mRNA,increases^expression
TSHZ2,rs6097145-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",6e-7,1.3604289,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSHZ2 mRNA",affects^cotreatment|decreases^expression
TSHZ2,rs6097145-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",6e-7,1.3604289,methylmercuric chloride,methylmercuric chloride results in decreased expression of TSHZ2 mRNA,decreases^expression
TSPOAP1-AS1,rs2526377-G,Alzheimer's disease,2e-12,0.95,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TSPOAP1-AS1 mRNA",affects^cotreatment|decreases^expression
TSPOAP1-AS1,rs2526377-G,Alzheimer's disease,2e-12,0.95,mercuric bromide,mercuric bromide results in decreased expression of TSPOAP1-AS1 mRNA,decreases^expression
TSPOAP1-AS1,rs2526377-G,Alzheimer's disease,2e-12,0.95,methylmercuric chloride,methylmercuric chloride results in decreased expression of TSPOAP1-AS1 mRNA,decreases^expression
UBE2QL1,rs553467-A,Alzheimer's disease,5e-7,1.6,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2QL1 mRNA",affects^cotreatment|decreases^expression
UBE2QL1,rs553467-A,Alzheimer's disease,5e-7,1.6,mercuric bromide,mercuric bromide results in decreased expression of UBE2QL1 mRNA,decreases^expression
UBE2QL1,rs553467-A,Alzheimer's disease,5e-7,1.6,methylmercuric chloride,methylmercuric chloride results in decreased expression of UBE2QL1 mRNA,decreases^expression
UBE2R2,rs144521193-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.5470582,Lead,Lead affects the splicing of UBE2R2 mRNA,affects^splicing
UBE2R2,rs144521193-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",3e-6,0.5470582,lead acetate,lead acetate results in increased expression of UBE2R2 mRNA,increases^expression
UBE2W,rs113926636-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.3909681,methylmercuric chloride,methylmercuric chloride results in decreased expression of UBE2W mRNA,decreases^expression
UGGT2,rs12877250-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",5e-6,1.4233311,methylmercuric chloride,methylmercuric chloride results in decreased expression of UGGT2 mRNA,decreases^expression
UQCRFS1,rs62111618-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",6e-6,1.3924991,Lead,Lead affects the methylation of UQCRFS1 gene,affects^methylation
USP13,rs142453422-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.61903095,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of USP13 mRNA",affects^cotreatment|decreases^expression
USP13,rs142453422-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",3e-6,0.61903095,lead acetate,[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP13 mRNA,affects^cotreatment|increases^expression
VAPA,rs28372356-?,Alzheimer's disease,2e-8,1.65,lead acetate,lead acetate results in decreased expression of VAPA protein,decreases^expression
VAPA,rs28372356-?,Alzheimer's disease,2e-8,1.65,methylmercuric chloride,methylmercuric chloride results in decreased expression of VAPA mRNA,decreases^expression
VAV2,rs79456223-C,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",9e-6,0.7239739,Lead,Lead affects the splicing of VAV2 mRNA,affects^splicing
VLDLR,rs1999521-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.2596073,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VLDLR mRNA",affects^cotreatment|increases^expression
VLDLR,rs1999521-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",6e-6,1.2596073,methylmercuric chloride,methylmercuric chloride results in increased expression of VLDLR mRNA,increases^expression
VSNL1,rs4038131-?,Psychosis and Alzheimer's disease,6e-7,1.5384616,Lead,Lead affects the expression of VSNL1 mRNA,affects^expression
VSNL1,rs4038131-?,Psychosis and Alzheimer's disease,6e-7,1.5384616,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VSNL1 mRNA",affects^cotreatment|decreases^expression
VSNL1,rs4038131-?,Psychosis and Alzheimer's disease,6e-7,1.5384616,methylmercuric chloride,methylmercuric chloride results in decreased expression of VSNL1 mRNA,decreases^expression
VTI1A,rs2479040-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.76177806,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VTI1A mRNA",affects^cotreatment|decreases^expression
VTI1A,rs2479040-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-7,0.76177806,methylmercuric chloride,methylmercuric chloride results in decreased expression of VTI1A mRNA,decreases^expression
WDR12,rs139643391-T,Alzheimer's disease,1e-8,0.94,methylmercuric chloride,methylmercuric chloride results in increased expression of WDR12 mRNA,increases^expression
WNT3,rs199515-G,Alzheimer's disease,9e-13,0.94,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT3 mRNA",affects^cotreatment|increases^expression
WWC1,rs113783161-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 3),5e-6,0.4251,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WWC1 mRNA",affects^cotreatment|increases^expression
XPR1,rs113811851-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 non-carriers",4e-6,0.6891475,methylmercuric chloride,methylmercuric chloride results in decreased expression of XPR1 mRNA,decreases^expression
XYLT1,rs149979242-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.68269986,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of XYLT1 mRNA",affects^cotreatment|decreases^expression
XYLT1,rs149979242-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,0.68269986,methylmercuric chloride,methylmercuric chloride results in decreased expression of XYLT1 mRNA,decreases^expression
XYLT2,rs140564244-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,1.343395,Lead,Lead affects the expression of XYLT2 mRNA,affects^expression
ZBTB16,rs441434-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),8e-6,2.319,Mercury,Mercury results in increased expression of ZBTB16 mRNA,increases^expression
ZBTB16,rs441434-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),8e-6,2.319,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZBTB16 mRNA",affects^cotreatment|decreases^expression
ZBTB16,rs441434-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),8e-6,2.319,mercuric bromide,mercuric bromide results in decreased expression of ZBTB16 mRNA,decreases^expression
ZBTB16,rs441434-?,Rapidly progressive Alzheimer's disease (clinical vs typical) (case-control set 3),8e-6,2.319,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZBTB16 mRNA,decreases^expression
ZBTB20,rs72948685-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",2e-6,1.2960225,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZBTB20 mRNA,decreases^expression
ZCCHC24,rs554149101-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",1e-5,1.6558261,Lead,Lead affects the expression of ZCCHC24 mRNA,affects^expression
ZFHX3,rs73594995-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,1.8059739,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFHX3 mRNA",affects^cotreatment|increases^expression
ZFYVE28,rs6599427-?,Rapidly progressive Alzheimer's disease (typical) (case-control set 3),8e-6,1.445,methylmercuric chloride,methylmercuric chloride results in increased expression of ZFYVE28 mRNA,increases^expression
ZIC5,rs9517934-?,Alzheimer's disease in APOE e4+ carriers,4e-6,1.896,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZIC5 mRNA",affects^cotreatment|decreases^expression
ZIC5,rs9517934-?,Alzheimer's disease in APOE e4+ carriers,4e-6,1.896,mercuric bromide,mercuric bromide results in decreased expression of ZIC5 mRNA,decreases^expression
ZIC5,rs9517934-?,Alzheimer's disease in APOE e4+ carriers,4e-6,1.896,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZIC5 mRNA,decreases^expression
ZMIZ1,rs2802372-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,1.1524614,Lead,Lead affects the splicing of ZMIZ1 mRNA,affects^splicing
ZMIZ1,rs2802372-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset >=75)",8e-6,1.1524614,methylmercuric chloride,methylmercuric chloride results in increased expression of ZMIZ1 mRNA,increases^expression
ZNF107,rs77330767-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",6e-6,0.64159375,Lead,Lead affects the expression of ZNF107 mRNA,affects^expression
ZNF180,rs141571465-G,"Alzheimer's disease, proxy Alzheimer's disease or related dementias (age of onset <75)",4e-6,1.3086551,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZNF180 mRNA,decreases^expression
ZNF184,rs2064220-?,Rapidly progressive Alzheimer's disease (pathologically-confirmed vs typical) (case-control set 3),5e-6,2.627,Lead,Lead affects the methylation of ZNF184 gene,affects^methylation
ZNF280C,rs209215-T,Alzheimer's disease,3e-6,1.02,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF280C mRNA",affects^cotreatment|decreases^expression
ZNF334,rs202380-T,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),3e-7,0.86,Phenylmercuric Acetate,Phenylmercuric Acetate results in decreased expression of ZNF334 mRNA,decreases^expression
ZNF334,rs202380-T,Alzheimer's disease or related dementias (adjusted for APOE E4 dosage),3e-7,0.86,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZNF334 mRNA,decreases^expression
ZNF385D,rs2638136-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.85667217,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385D mRNA",affects^cotreatment|decreases^expression
ZNF385D,rs2638136-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.85667217,mercuric bromide,mercuric bromide results in decreased expression of ZNF385D mRNA,decreases^expression
ZNF385D,rs2638136-A,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",1e-6,0.85667217,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZNF385D mRNA,decreases^expression
ZNF608,rs11748437-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias",5e-6,0.69440496,methylmercuric chloride,methylmercuric chloride results in decreased expression of ZNF608 mRNA,decreases^expression
ZNRF3,rs932302-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",3e-6,0.80686414,Phenylmercuric Acetate,"[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZNRF3 mRNA",affects^cotreatment|increases^expression
ZNRF3,rs932302-T,"Alzheimer's disease, proxy Alzheimer's disease or related dementias in APOE e4 carriers",3e-6,0.80686414,methylmercuric chloride,methylmercuric chloride results in increased expression of ZNRF3 mRNA,increases^expression
